AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsHealth Care
Pulmonary FibrosisIdiopathic Pulmonary FibrosisFibrosisBleomycinCystic FibrosisLungHydroxyprolineLung Diseases, InterstitialBronchoalveolar Lavage FluidFibroblastsMyofibroblastsPulmonary AlveoliCystic Fibrosis Transmembrane Conductance RegulatorAlveolitis, Extrinsic AllergicCollagenCollagen DiseasesTransforming Growth Factor betaScleroderma, SystemicEndomyocardial FibrosisPeplomycinMice, Inbred C57BLRespiratory Function TestsTransforming Growth Factor beta1Disease Models, AnimalLung TransplantationSarcoidosis, PulmonaryPulmonary EmphysemaAntibiotics, AntineoplasticLiver CirrhosisBronchoalveolar LavageHermanski-Pudlak SyndromePyridonesAsbestosisRetroperitoneal FibrosisPulmonary Surfactant-Associated Protein CMacrophages, AlveolarPneumocytesAsbestosCollagen Type IIIIdiopathic Interstitial PneumoniasLung DiseasesVital CapacityLung InjuryCollagen Type ICryptogenic Organizing PneumoniaPulmonary Diffusing CapacityRespiratory MucosaMice, KnockoutPneumoniaDisease ProgressionBiopsySilicon DioxideSarcoidosisEpithelial CellsSilicosisHSP47 Heat-Shock ProteinsRespiratory System AgentsBiological MarkersHypertension, PulmonarySmad3 ProteinCells, CulturedImmunohistochemistryTotal Lung CapacityConnective Tissue Growth FactorTomography, X-Ray ComputedRNA, MessengerMucin-5BRadiation PneumonitisExtracellular MatrixPulmonary Surfactant-Associated Protein APleural DiseasesActinsSignal TransductionOral Submucous FibrosisAmbroxolConnective Tissue DiseasesEpithelial-Mesenchymal TransitionTime FactorsDyspneaLiver Cirrhosis, ExperimentalSmad2 ProteinRespiratory AspirationInflammationProcollagenExpectorantsGene Expression RegulationRetrospective StudiesSeverity of Illness IndexPneumoconiosisCytokinesGene ExpressionMice, TransgenicSmad ProteinsScleroderma, DiffuseParaquatInterleukin-13TelomeraseGammaherpesvirinaeHepatic Stellate CellsPhenotype
Pulmonary Fibrosis
A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.
Idiopathic Pulmonary Fibrosis
A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.
Fibrosis
Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
Bleomycin
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.
Cystic Fibrosis
An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
Lung
Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood.
Hydroxyproline
A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation.
Lung Diseases, Interstitial
A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.
Bronchoalveolar Lavage Fluid
Washing liquid obtained from irrigation of the lung, including the BRONCHI and the PULMONARY ALVEOLI. It is generally used to assess biochemical, inflammatory, or infection status of the lung.
Fibroblasts
Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules.
Myofibroblasts
Spindle-shaped cells with characteristic CONTRACTILE PROTEINS and structures that contribute to the WOUND HEALING process. They occur in GRANULATION TISSUE and also in pathological processes such as FIBROSIS.
Pulmonary Alveoli
Small polyhedral outpouchings along the walls of the alveolar sacs, alveolar ducts and terminal bronchioles through the walls of which gas exchange between alveolar air and pulmonary capillary blood takes place.
Cystic Fibrosis Transmembrane Conductance Regulator
A chloride channel that regulates secretion in many exocrine tissues. Abnormalities in the CFTR gene have been shown to cause cystic fibrosis. (Hum Genet 1994;93(4):364-8)
Alveolitis, Extrinsic Allergic
A common interstitial lung disease caused by hypersensitivity reactions of PULMONARY ALVEOLI after inhalation of and sensitization to environmental antigens of microbial, animal, or chemical sources. The disease is characterized by lymphocytic alveolitis and granulomatous pneumonitis.
Collagen
A polypeptide substance comprising about one third of the total protein in mammalian organisms. It is the main constituent of SKIN; CONNECTIVE TISSUE; and the organic substance of bones (BONE AND BONES) and teeth (TOOTH).
Collagen Diseases
Historically, a heterogeneous group of acute and chronic diseases, including rheumatoid arthritis, systemic lupus erythematosus, progressive systemic sclerosis, dermatomyositis, etc. This classification was based on the notion that "collagen" was equivalent to "connective tissue", but with the present recognition of the different types of collagen and the aggregates derived from them as distinct entities, the term "collagen diseases" now pertains exclusively to those inherited conditions in which the primary defect is at the gene level and affects collagen biosynthesis, post-translational modification, or extracellular processing directly. (From Cecil Textbook of Medicine, 19th ed, p1494)
Transforming Growth Factor beta
A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.
Scleroderma, Systemic
A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
Endomyocardial Fibrosis
A condition characterized by the thickening of the ventricular ENDOCARDIUM and subendocardium (MYOCARDIUM), seen mostly in children and young adults in the TROPICAL CLIMATE. The fibrous tissue extends from the apex toward and often involves the HEART VALVES causing restrictive blood flow into the respective ventricles (CARDIOMYOPATHY, RESTRICTIVE).
Peplomycin
An antineoplastic agent derived from BLEOMYCIN.
Mice, Inbred C57BL
Respiratory Function Tests
Measurement of the various processes involved in the act of respiration: inspiration, expiration, oxygen and carbon dioxide exchange, lung volume and compliance, etc.
Transforming Growth Factor beta1
A subtype of transforming growth factor beta that is synthesized by a wide variety of cells. It is synthesized as a precursor molecule that is cleaved to form mature TGF-beta 1 and TGF-beta1 latency-associated peptide. The association of the cleavage products results in the formation a latent protein which must be activated to bind its receptor. Defects in the gene that encodes TGF-beta1 are the cause of CAMURATI-ENGELMANN SYNDROME.
Disease Models, Animal
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Lung Transplantation
The transference of either one or both of the lungs from one human or animal to another.
Sarcoidosis, Pulmonary
Sarcoidosis affecting predominantly the lungs, the site most frequently involved and most commonly causing morbidity and mortality in sarcoidosis. Pulmonary sarcoidosis is characterized by sharply circumscribed granulomas in the alveolar, bronchial, and vascular walls, composed of tightly packed cells derived from the mononuclear phagocyte system. The clinical symptoms when present are dyspnea upon exertion, nonproductive cough, and wheezing. (Cecil Textbook of Medicine, 19th ed, p431)
Pulmonary Emphysema
Enlargement of air spaces distal to the TERMINAL BRONCHIOLES where gas-exchange normally takes place. This is usually due to destruction of the alveolar wall. Pulmonary emphysema can be classified by the location and distribution of the lesions.
Antibiotics, Antineoplastic
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.
Liver Cirrhosis
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
Bronchoalveolar Lavage
Washing out of the lungs with saline or mucolytic agents for diagnostic or therapeutic purposes. It is very useful in the diagnosis of diffuse pulmonary infiltrates in immunosuppressed patients.
Hermanski-Pudlak Syndrome
Syndrome characterized by the triad of oculocutaneous albinism (ALBINISM, OCULOCUTANEOUS); PLATELET STORAGE POOL DEFICIENCY; and lysosomal accumulation of ceroid lipofuscin.
Pyridones
Pyridine derivatives with one or more keto groups on the ring.
Asbestosis
A form of pneumoconiosis caused by inhalation of asbestos fibers which elicit potent inflammatory responses in the parenchyma of the lung. The disease is characterized by interstitial fibrosis of the lung, varying from scattered sites to extensive scarring of the alveolar interstitium.
Retroperitoneal Fibrosis
A slowly progressive condition of unknown etiology, characterized by deposition of fibrous tissue in the retroperitoneal space compressing the ureters, great vessels, bile duct, and other structures. When associated with abdominal aortic aneurysm, it may be called chronic periaortitis or inflammatory perianeurysmal fibrosis.
Pulmonary Surfactant-Associated Protein C
A pulmonary surfactant associated protein that plays a role in alveolar stability by lowering the surface tension at the air-liquid interface. It is a membrane-bound protein that constitutes 1-2% of the pulmonary surfactant mass. Pulmonary surfactant-associated protein C is one of the most hydrophobic peptides yet isolated and contains an alpha-helical domain with a central poly-valine segment that binds to phospholipid bilayers.
Macrophages, Alveolar
Round, granular, mononuclear phagocytes found in the alveoli of the lungs. They ingest small inhaled particles resulting in degradation and presentation of the antigen to immunocompetent cells.
Pneumocytes
Epithelial cells that line the PULMONARY ALVEOLI.
Asbestos
Asbestos. Fibrous incombustible mineral composed of magnesium and calcium silicates with or without other elements. It is relatively inert chemically and used in thermal insulation and fireproofing. Inhalation of dust causes asbestosis and later lung and gastrointestinal neoplasms.
Collagen Type III
A fibrillar collagen consisting of three identical alpha1(III) chains that is widely distributed in many tissues containing COLLAGEN TYPE I. It is particularly abundant in BLOOD VESSELS and may play a role in tissues with elastic characteristics.
Idiopathic Interstitial Pneumonias
A group of interstitial lung diseases with no known etiology. There are several entities with varying patterns of inflammation and fibrosis. They are classified by their distinct clinical-radiological-pathological features and prognosis. They include IDIOPATHIC PULMONARY FIBROSIS; CRYPTOGENIC ORGANIZING PNEUMONIA; and others.
Lung Diseases
Pathological processes involving any part of the LUNG.
Vital Capacity
The volume of air that is exhaled by a maximal expiration following a maximal inspiration.
Lung Injury
Damage to any compartment of the lung caused by physical, chemical, or biological agents which characteristically elicit inflammatory reaction. These inflammatory reactions can either be acute and dominated by NEUTROPHILS, or chronic and dominated by LYMPHOCYTES and MACROPHAGES.
Collagen Type I
The most common form of fibrillar collagen. It is a major constituent of bone (BONE AND BONES) and SKIN and consists of a heterotrimer of two alpha1(I) and one alpha2(I) chains.
Cryptogenic Organizing Pneumonia
An interstitial lung disease of unknown etiology, occurring between 21-80 years of age. It is characterized by a dramatic onset of a "pneumonia-like" illness with cough, fever, malaise, fatigue, and weight loss. Pathological features include prominent interstitial inflammation without collagen fibrosis, diffuse fibroblastic foci, and no microscopic honeycomb change. There is excessive proliferation of granulation tissue within small airways and alveolar ducts.
Pulmonary Diffusing Capacity
The amount of a gas taken up, by the pulmonary capillary blood from the alveolar gas, per minute per unit of average pressure of the gradient of the gas across the BLOOD-AIR BARRIER.
Respiratory Mucosa
The mucous membrane lining the RESPIRATORY TRACT, including the NASAL CAVITY; the LARYNX; the TRACHEA; and the BRONCHI tree. The respiratory mucosa consists of various types of epithelial cells ranging from ciliated columnar to simple squamous, mucous GOBLET CELLS, and glands containing both mucous and serous cells.
Mice, Knockout
Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.
Pneumonia
Infection of the lung often accompanied by inflammation.
Disease Progression
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Biopsy
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
Silicon Dioxide
Transparent, tasteless crystals found in nature as agate, amethyst, chalcedony, cristobalite, flint, sand, QUARTZ, and tridymite. The compound is insoluble in water or acids except hydrofluoric acid.
Sarcoidosis
An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands.
Epithelial Cells
Cells that line the inner and outer surfaces of the body by forming cellular layers (EPITHELIUM) or masses. Epithelial cells lining the SKIN; the MOUTH; the NOSE; and the ANAL CANAL derive from ectoderm; those lining the RESPIRATORY SYSTEM and the DIGESTIVE SYSTEM derive from endoderm; others (CARDIOVASCULAR SYSTEM and LYMPHATIC SYSTEM) derive from mesoderm. Epithelial cells can be classified mainly by cell shape and function into squamous, glandular and transitional epithelial cells.
Silicosis
A form of pneumoconiosis resulting from inhalation of dust containing crystalline form of SILICON DIOXIDE, usually in the form of quartz. Amorphous silica is relatively nontoxic.
HSP47 Heat-Shock Proteins
Basic glycoprotein members of the SERPIN SUPERFAMILY that function as COLLAGEN-specific MOLECULAR CHAPERONES in the ENDOPLASMIC RETICULUM.
Respiratory System Agents
Drugs used for their effects on the respiratory system.
Biological Markers
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
Hypertension, Pulmonary
Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
Smad3 Protein
A receptor-regulated smad protein that undergoes PHOSPHORYLATION by ACTIVIN RECEPTORS, TYPE I. Activated Smad3 can bind directly to DNA, and it regulates TRANSFORMING GROWTH FACTOR BETA and ACTIVIN signaling.
Cells, Cultured
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Immunohistochemistry
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Total Lung Capacity
The volume of air contained in the lungs at the end of a maximal inspiration. It is the equivalent to each of the following sums: VITAL CAPACITY plus RESIDUAL VOLUME; INSPIRATORY CAPACITY plus FUNCTIONAL RESIDUAL CAPACITY; TIDAL VOLUME plus INSPIRATORY RESERVE VOLUME plus functional residual capacity; or tidal volume plus inspiratory reserve volume plus EXPIRATORY RESERVE VOLUME plus residual volume.
Connective Tissue Growth Factor
A CCN protein family member that regulates a variety of extracellular functions including CELL ADHESION; CELL MIGRATION; and EXTRACELLULAR MATRIX synthesis. It is found in hypertrophic CHONDROCYTES where it may play a role in CHONDROGENESIS and endochondral ossification.
Tomography, X-Ray Computed
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
RNA, Messenger
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Mucin-5B
A gel-forming mucin that is predominantly expressed by submucosal glands of airway tissues and the SUBLINGUAL GLAND. It is one of the principal components of high molecular weight salivary mucin.
Radiation Pneumonitis
Inflammation of the lung due to harmful effects of ionizing or non-ionizing radiation.
Extracellular Matrix
A meshwork-like substance found within the extracellular space and in association with the basement membrane of the cell surface. It promotes cellular proliferation and provides a supporting structure to which cells or cell lysates in culture dishes adhere.
Pulmonary Surfactant-Associated Protein A
An abundant pulmonary surfactant-associated protein that binds to a variety of lung pathogens, resulting in their opsinization. It also stimulates MACROPHAGES to undergo PHAGOCYTOSIS of microorganisms. Surfactant protein A contains a N-terminal collagen-like domain and a C-terminal lectin domain that are characteristic of members of the collectin family of proteins.
Pleural Diseases
Actins
Filamentous proteins that are the main constituent of the thin filaments of muscle fibers. The filaments (known also as filamentous or F-actin) can be dissociated into their globular subunits; each subunit is composed of a single polypeptide 375 amino acids long. This is known as globular or G-actin. In conjunction with MYOSINS, actin is responsible for the contraction and relaxation of muscle.
Signal Transduction
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
Oral Submucous Fibrosis
Ambroxol
A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride.
Connective Tissue Diseases
A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides.
Epithelial-Mesenchymal Transition
Phenotypic changes of EPITHELIAL CELLS to MESENCHYME type, which increase cell mobility critical in many developmental processes such as NEURAL TUBE development. NEOPLASM METASTASIS and DISEASE PROGRESSION may also induce this transition.
Time Factors
Elements of limited time intervals, contributing to particular results or situations.
Dyspnea
Difficult or labored breathing.
Liver Cirrhosis, Experimental
Experimentally induced chronic injuries to the parenchymal cells in the liver to achieve a model for LIVER CIRRHOSIS.
Smad2 Protein
A receptor-regulated smad protein that undergoes PHOSPHORYLATION by ACTIVIN RECEPTORS, TYPE I. It regulates TRANSFORMING GROWTH FACTOR BETA and ACTIVIN signaling.
Respiratory Aspiration
Inhaling liquid or solids, such as stomach contents, into the RESPIRATORY TRACT. When this causes severe lung damage, it is called ASPIRATION PNEUMONIA.
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
Procollagen
A biosynthetic precursor of collagen containing additional amino acid sequences at the amino-terminal and carboxyl-terminal ends of the polypeptide chains.
Expectorants
Agents that increase mucous excretion. Mucolytic agents, that is drugs that liquefy mucous secretions, are also included here.
Gene Expression Regulation
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation.
Retrospective Studies
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Severity of Illness Index
Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.
Pneumoconiosis
A diffuse parenchymal lung disease caused by inhalation of dust and by tissue reaction to their presence. These inorganic, organic, particulate, or vaporized matters usually are inhaled by workers in their occupational environment, leading to the various forms (ASBESTOSIS; BYSSINOSIS; and others). Similar air pollution can also have deleterious effects on the general population.
Cytokines
Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner.
Gene Expression
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
Mice, Transgenic
Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.
Smad Proteins
A family of proteins that are involved in the translocation of signals from TGF-BETA RECEPTORS; BONE MORPHOGENETIC PROTEIN RECEPTORS; and other surface receptors to the CELL NUCLEUS. They were originally identified as a class of proteins that are related to the mothers against decapentaplegic protein, Drosophila and sma proteins from CAENORHABDITIS ELEGANS.
Scleroderma, Diffuse
A rapid onset form of SYSTEMIC SCLERODERMA with progressive widespread SKIN thickening over the arms, the legs and the trunk, resulting in stiffness and disability.
Paraquat
A poisonous dipyridilium compound used as contact herbicide. Contact with concentrated solutions causes irritation of the skin, cracking and shedding of the nails, and delayed healing of cuts and wounds.
Interleukin-13
A cytokine synthesized by T-LYMPHOCYTES that produces proliferation, immunoglobulin isotype switching, and immunoglobulin production by immature B-LYMPHOCYTES. It appears to play a role in regulating inflammatory and immune responses.
Telomerase
An essential ribonucleoprotein reverse transcriptase that adds telomeric DNA to the ends of eukaryotic CHROMOSOMES.
Gammaherpesvirinae
A subfamily of HERPESVIRIDAE characterized by variable reproductive cycles. The genera include: LYMPHOCRYPTOVIRUS and RHADINOVIRUS.
Hepatic Stellate Cells
Perisinusoidal cells of the liver, located in the space of Disse between HEPATOCYTES and sinusoidal endothelial cells.
Phenotype
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
Macrophages
The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.)
Epithelium
One or more layers of EPITHELIAL CELLS, supported by the basal lamina, which covers the inner or outer surfaces of the body.
Emphysema
A pathological accumulation of air in tissues or organs.
Forced Expiratory Volume
Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity.
Ureteral Obstruction
Blockage in any part of the URETER causing obstruction of urine flow from the kidney to the URINARY BLADDER. The obstruction may be congenital, acquired, unilateral, bilateral, complete, partial, acute, or chronic. Depending on the degree and duration of the obstruction, clinical features vary greatly such as HYDRONEPHROSIS and obstructive nephropathy.
Up-Regulation
A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
Pseudomonas Infections
Infections with bacteria of the genus PSEUDOMONAS.
Pulmonary Surfactant-Associated Protein D
An abundant pulmonary surfactant-associated protein that binds to a variety of lung pathogens and enhances their opsinization and killing by phagocytic cells. Surfactant protein D contains a N-terminal collagen-like domain and a C-terminal lectin domain that are characteristic of members of the collectin family of proteins.
Case-Control Studies
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
Instillation, Drug
The administration of therapeutic agents drop by drop, as eye drops, ear drops, or nose drops. It is also administered into a body space or cavity through a catheter. It differs from THERAPEUTIC IRRIGATION in that the irrigate is removed within minutes, but the instillate is left in place.
Therapeutic Irrigation
The washing of a body cavity or surface by flowing water or solution for therapy or diagnosis.
Scleroderma, Limited
The least progressive form of SYSTEMIC SCLERODERMA with skin thickening restricted to the face, neck and areas distal to the elbows and/or knees, sparing the trunk. The CREST SYNDROME is a form of limited scleroderma.
Reverse Transcriptase Polymerase Chain Reaction
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
Leukocyte Elastase
An enzyme that catalyzes the hydrolysis of proteins, including elastin. It cleaves preferentially bonds at the carboxyl side of Ala and Val, with greater specificity for Ala. EC 3.4.21.37.
Blotting, Western
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
Prednisolone
A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
Cell Proliferation
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
Enzyme-Linked Immunosorbent Assay
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
Bronchi
The larger air passages of the lungs arising from the terminal bifurcation of the TRACHEA. They include the largest two primary bronchi which branch out into secondary bronchi, and tertiary bronchi which extend into BRONCHIOLES and PULMONARY ALVEOLI.
Carbon Tetrachloride
A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed)
Rats, Sprague-Dawley
A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company.
Fibronectins
Glycoproteins found on the surfaces of cells, particularly in fibrillar structures. The proteins are lost or reduced when these cells undergo viral or chemical transformation. They are highly susceptible to proteolysis and are substrates for activated blood coagulation factor VIII. The forms present in plasma are called cold-insoluble globulins.
Prognosis
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Chemokine CCL17
A CC-type chemokine that is found at high levels in the THYMUS and has specificity for CCR4 RECEPTORS. It is synthesized by DENDRITIC CELLS; ENDOTHELIAL CELLS; KERATINOCYTES; and FIBROBLASTS.
Matrix Metalloproteinase 7
The smallest member of the MATRIX METALLOPROTEINASES. It plays a role in tumor progression.
Pseudomonas aeruginosa
A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection.
Cell Line
Established cell cultures that have the potential to propagate indefinitely.
Asbestos, Serpentine
A type of asbestos that occurs in nature as the dihydrate of magnesium silicate. It exists in two forms: antigorite, a plated variety, and chrysotile, a fibrous variety. The latter makes up 95% of all asbestos products. (From Merck Index, 11th ed, p.893)
Peritoneal Fibrosis
Disorder characterized by a wide range of structural changes in PERITONEUM, resulting from fibrogenic or inflammatory processes. Peritoneal fibrosis is a common complication in patients receiving PERITONEAL DIALYSIS and contributes to its gradual decrease in efficiency.
Acetylcysteine
The N-acetyl derivative of CYSTEINE. It is used as a mucolytic agent to reduce the viscosity of mucous secretions. It has also been shown to have antiviral effects in patients with HIV due to inhibition of viral stimulation by reactive oxygen intermediates.
Intercellular Signaling Peptides and Proteins
Regulatory proteins and peptides that are signaling molecules involved in the process of PARACRINE COMMUNICATION. They are generally considered factors that are expressed by one cell and are responded to by receptors on another nearby cell. They are distinguished from HORMONES in that their actions are local rather than distal.
Rats, Inbred F344
Pleura
The thin serous membrane enveloping the lungs (LUNG) and lining the THORACIC CAVITY. Pleura consist of two layers, the inner visceral pleura lying next to the pulmonary parenchyma and the outer parietal pleura. Between the two layers is the PLEURAL CAVITY which contains a thin film of liquid.
Chemokine CXCL5
A CXC chemokine that is predominantly expressed in EPITHELIAL CELLS. It has specificity for the CXCR2 RECEPTORS and is involved in the recruitment and activation of NEUTROPHILS.
Treatment Outcome
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Bronchiectasis
Persistent abnormal dilatation of the bronchi.

The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. (1/2241)

Transforming growth factor beta (TGF beta) family members are secreted in inactive complexes with a latency-associated peptide (LAP), a protein derived from the N-terminal region of the TGF beta gene product. Extracellular activation of these complexes is a critical but incompletely understood step in regulation of TGF beta function in vivo. We show that TGF beta 1 LAP is a ligand for the integrin alpha v beta 6 and that alpha v beta 6-expressing cells induce spatially restricted activation of TGF beta 1. This finding explains why mice lacking this integrin develop exaggerated inflammation and, as we show, are protected from pulmonary fibrosis. These data identify a novel mechanism for locally regulating TGF beta 1 function in vivo by regulating expression of the alpha v beta 6 integrin.  (+info)

Idiopathic pulmonary haemosiderosis. Epidemiology, pathogenic aspects and diagnosis. (2/2241)

Idiopathic pulmonary haemosiderosis (IPH) is a rare clinical entity characterized by recurrent episodes of diffuse alveolar haemorrhage, often presenting with haemoptysis. Many patients have iron deficiency anaemia due to deposition of haemosiderin iron in the alveoli, and eventually develop moderate pulmonary fibrosis. Typically, intensive search for an aetiology ends up negative. There is no evidence of pulmonary vasculitis or capillaritis. The aetiology is obscure, but may be an immunological or toxic mechanism causing a defect in the basement membrane of the pulmonary capillary. IPH affects both children and adults. During an acute episode, a chest X-ray demonstrates bilateral, alveolar infiltrates. Sputum examination discloses haemosiderin-laden alveolar macrophages. Diagnosis is established by lung biopsy (fiber-optic or thoracoscopic), showing large numbers of haemosiderin-laden macrophages in the alveoli and without evidence of capillaritis or deposition of immunoglobulins. Corticosteroids and/or immunosuppressive drugs may be effective during an acute bleeding episode, and may in some patients improve symptoms and prognosis on the long-term, but the response to treatment displays great interindividual variation.  (+info)

Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. (3/2241)

Interleukin (IL)-13 is a pleiotropic cytokine produced in large quantities by activated CD4(+) Th2 lymphocytes. To define further its potential in vivo effector functions, the Clara cell 10-kDa protein promoter was used to express IL-13 selectively in the lung, and the phenotype of the resulting transgenic mice was characterized. In contrast to transgene-negative littermates, the lungs of transgene-positive mice contained an inflammatory response around small and large airways and in the surrounding parenchyma. It was mononuclear in nature and contained significant numbers of eosinophils and enlarged and occasionally multinucleated macrophages. Airway epithelial cell hypertrophy, mucus cell metaplasia, the hyperproduction of neutral and acidic mucus, the deposition of Charcot-Leyden-like crystals, and subepithelial airway fibrosis were also prominently noted. Eotaxin protein and mRNA were also present in large quantities in the lungs of the transgene-positive, but not the transgene-negative, mice. IL-4, IL-5, granulocyte-macrophage colony-stimulating factor, and monocyte chemoattractant protein-5 were not similarly detected. Physiological evaluations revealed significant increases in baseline airways resistance and airways hyperresponsiveness (AHR) to methacholine in transgene-positive animals. Thus, the targeted pulmonary expression of IL-13 causes a mononuclear and eosinophilic inflammatory response, mucus cell metaplasia, the deposition of Charcot-Leyden-like crystals, airway fibrosis, eotaxin production, airways obstruction, and nonspecific AHR. IL-13 may play an important role in the pathogenesis of similar responses in asthma or other Th2-polarized tissue responses.  (+info)

Reduced tumor necrosis factor-alpha and transforming growth factor-beta1 expression in the lungs of inbred mice that fail to develop fibroproliferative lesions consequent to asbestos exposure. (4/2241)

Tumor necrosis factor (TNF)-alpha and transforming growth factor (TGF)-beta mRNA and protein expression and the degree of fibroproliferative response to inhaled asbestos fibers are clearly reduced in the 129 inbred mouse strain as compared with typical fibrogenesis observed in the C57BL/6 inbred strain. The C57BL/6 mice showed prominent lesions at bronchiolar-alveolar duct (BAD) junctions where asbestos fibers deposit and responding macrophages accumulate. The 129 mice, however, were generally indistinguishable from controls even though the numbers of asbestos fibers deposited in the lungs of all exposed animals were the same. Quantitative morphometry of H&E-stained lung sections comparing the C57BL/6 and 129 mice showed significantly less mean cross-sectional area of the BAD junctions in the 129 animals, apparent at both 48 hours and 4 weeks after exposure. In addition, fewer macrophages had accumulated at these sites in the 129 mice. Nuclear bromodeoxyuridine immunostaining demonstrated that the number of proliferating cells at first alveolar duct bifurcations and in adjacent terminal bronchioles was significantly reduced in the 129 strain compared with C57BL/6 mice at 48 hours after exposure (P < 0.01). TNF-alpha and TGF-beta1 gene expression, as measured by in situ hybridization, was reduced in the 129 mice at 48 hours after exposure, and expression of TNF-alpha and TGF-beta1 protein, as measured by immunohistochemistry, was similarly reduced or absent in the 129 animals. We postulate that the protection afforded the 129 mice is related to reduction of growth factor expression by the bronchiolar-alveolar epithelium and lung macrophages.  (+info)

Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. (5/2241)

A time course study was carried out to elucidate the mechanisms for antifibrotic effect of pirfenidone (PD). Hamsters were intratracheally (i.t.) instilled with saline (SA) or bleomycin (BL) (7.5 units/kg/5 ml). The animals were fed a diet containing 0.5% PD or the same control diet (CD) without the drug 2 days before and throughout the study. The animals were sacrificed at various times after instillation. The lung hydroxyproline level in BL + CD groups was gradually increased and peaked at 21 days to 181% of the SA + CD control. The BL + PD-treated groups showed a gradual decrease in their lung collagen content, showing a maximum reduction of 40% at day 21. The lung malondialdehyde levels of the BL + CD groups were increased by several-fold of the corresponding SA + CD groups at various times. The lung prolyl hydroxylase (PH) activities in the BL + CD groups were also increased by several-fold of the corresponding SA + CD groups at these time points. The hamsters in the BL + PD showed a gradual decrease in the lung malondialdehyde levels from 10 to 21days compared with their corresponding BL + CD groups. Treatment with PD also reduced the lung PH activities in the BL + PD groups compared with the corresponding BL + CD groups. However, PD failed to manifest any direct inhibitory effect on PH activity in vitro. BL treatment increased the lung procollagen I and III gene expressions in the BL + CD groups by several-fold at varying times compared with the corresponding SA + CD, and treatment with PD in the BL + PD groups significantly down-regulated the BL-induced overexpression of these genes. Studies evaluating the regulation of these genes at the transcriptional level revealed PD significantly reduced the transcription of PC I at 14 days. Our results indicate that the antifibrotic effect of PD was partly due to suppression of the BL-induced inflammatory events and partly due to down-regulation of BL-induced overexpression of lung procollagen I and III genes.  (+info)

T cell independence of bleomycin-induced pulmonary fibrosis. (6/2241)

The role of T cells and cytokines in bleomycin (BLM)-induced fibrosis was evaluated in susceptible and resistant strains of normal and SCID mice. Histology and hydroxyproline analysis showed that BLM induced pulmonary fibrosis in C57BL/6 and (C57BL/6 x BALB/c)F1 mice, whereas BALB/c mice were resistant to the disease. To test whether lymphocytes were required for the induction of BLM-induced pulmonary fibrosis, SCID mice were injected intratracheally with BLM and evaluated for the development of pulmonary inflammation and fibrosis. Similar morphological changes and increases in hydroxyproline were observed in both C57BL/6 SCID and (C57BL/6 x CB.17)F1 SCID animals compared to those seen in wild-type C57BL/6 and (C57BL/6 x BALB/c)F1 mice. In contrast, CB.17 SCID mice, which are genetically similar to BALB/c mice, were resistant to disease induction. Analysis of the cellular infiltrate in BLM-treated C57Bl/6 SCID mice confirmed a lack of T cells in the lungs of SCID mice and demonstrated a pronounced accumulation of eosinophils in areas of developing pulmonary fibrosis. NK cells were significantly elevated in untreated SCID mice and did not increase further after BLM treatment. Analysis of selected cytokines 1 day after initiation of BLM-induced pulmonary fibrosis indicated that the levels of TNF-alpha and IFN-gamma appeared to segregate with fibrosis in both the SCID and wild-type mice. The data demonstrate that T cells are not required for the induction of fibrosis by BLM and suggest that responses by non-lymphoid cells may be sufficient for the induction of fibrosis.  (+info)

Structural elucidation of a novel exopolysaccharide produced by a mucoid clinical isolate of Burkholderia cepacia. Characterization of a trisubstituted glucuronic acid residue in a heptasaccharide repeating unit. (7/2241)

The structure of the exopolysaccharide (EPS) produced by a clinical isolate of Burkholderia cepacia isolated from a patient with fibrocystic lung disease has been investigated. By means of methylation analyses, carboxyl reduction, partial depolymerization by fuming HCl and chemical degradations such as Smith degradation, lithiumethylenediamine degradation and beta-elimination, supported by GC/MS and NMR spectroscopic analyses, the repeat unit of the EPS has been identified and was shown to correspond to the acidic branched heptasaccharide with the following structure: [formula: see text]. This partially acetylated acidic polymer, distinguished by the presence of the less usual D-isomer of rhamnose and of a trisubstituted glucuronic acid residue, could represent the main EPS produced by this bacterial species.  (+info)

In search of a cause of cryptogenic fibrosing alveolitis (CFA): one initiating factor or many? (8/2241)

The history of patients with idiopathic pulmonary fibrosis (IPF) shows that the disease may be preceded by a viral-like illness. Although viruses have not been demonstrated, it is possible that viruses were not detected in culture because they do not replicate during latency. We investigated the presence of adenovirus in IPF and interstitial pneumonia associated with collagen vascular disease (CVD-IP), using the nested polymerase chain reaction (PCR) and in situ hybridization (ISH) for the E1A region of the adenovirus genome. Studies were performed on lung tissues obtained by transbronchial lung biopsy from 19 patients with IPF, 10 patients with CVD-IP and, for comparison, 20 patients with sarcoidosis. The E1A DNA was present in 3 out of 19 (16%) cases of IPF, in 5 of 10 (50%) cases of CVD-IP, and in 2 of 20 (10%) cases of sarcoidosis. The incidence of E1A DNA in CVD-IP was significantly higher than that in sarcoidosis (p < 0.05). In patients with IPF and CVD-IP, E1A DNA was more prevalent in patients treated with corticosteroids (6 out of 9 cases; 67%) than in those without it (2 out of 20 cases; 10%) (p < 0.01). ISH studies showed that 1 out of 8 cases of IPF and CVD-IP, in which E1A DNA was detected by PCR, was positive for E1A DNA. We conclude that adenovirus E1A is unlikely to be aetiologically involved in the pathogenesis of idiopathic pulmonary fibrosis or interstitial pneumonia associated with collagen vascular disease. However, a latent adenovirus infection may be reactivated or may newly infect the host following corticosteroid administration.  (+info)

Blue bodies in a case of cryptogenic fibrosing alveolitis (desquamative type) an ultra-structural study. |...Blue bodies in a case of cryptogenic fibrosing alveolitis (desquamative type) an ultra-structural study. |...
A patient with cryptogenic fibrosing alveolitis, with both mural and desquamative features, had two lung biopsies at the times of coronary artery surgery. These lung specimens were studied, using light and electron microscopy, with immunofluorescence techniques and electron microanalysis. In addition to the typical changes of cryptogenic fibrosing alveolitis previously reported, we found blue-staining bodies within alveolar macrophages and giant cells. These bodies were 15--25 micrometer in diameter with an iron rich outer rim and core of connective tissue mucin--possibly chondroitin sulphate or dermatan sulphate. It seems unlikely that these blue bodies were due to fibreglass dust to which the patients had had a trivial exposure, but their exact nature and significance remains unclear.. ...
http://thorax.bmj.com/content/33/6/806
Familial interstitial pulmonary fibrosis
Relief is when you and the right researcher find each other Finding the right clinical trial for Familial interstitial pulmonary fibrosis can be challenging. However, with TrialsFinder (which uses the Reg4ALL database and privacy controls by Private Access), you can permit researchers to let you know opportunities to consider - all without revealing your identity. ...
http://diseaseinfosearch.org/Familial+interstitial+pulmonary++fibrosis/2755
Interstitial Pulmonary fibrosis ( Causes - C/P - Investigations - Treatment ) [Archive] - Medical Educational WebInterstitial Pulmonary fibrosis ( Causes - C/P - Investigations - Treatment ) [Archive] - Medical Educational Web
Interstitial Pulmonary fibrosis Def. group of diseases characterized by infiltration of the interstitial tissue of the lung by abnormal tissue. Site of pathology = Interstitial tissue (in between alveoli) = Peri-alveolar tissue. Pathogenesis Exposure to dust (for example) ► Trigger immune system Or ► Inflammatory reaction Or ► Direct toxicity
https://www.meduweb.com/archive/index.php/t-6912.html?s=5f3211b00f05f7228be4fee59403e8e5
Positive Antinuclear Factor in Patients with Unexplained Pulmonary Fibrosis | Annals of Internal Medicine | American College of...Positive Antinuclear Factor in Patients with Unexplained Pulmonary Fibrosis | Annals of Internal Medicine | American College of...
SUMMARY. Twenty patients with unexplained pulmonary fibrosis and circulating antinuclear factor were identified. Diseases commonly associated with antinuclear factor, such as systemic lupus erythematosus or scleroderma, were excluded. Half of the patients showed typical restrictive ventilatory defects and X-ray evidence of severe fibrotic changes. The remaining patients predominantly had evidence of obstructive airway diseases.. Four lung biopsies were available. Three showed histological evidence of interstitial pulmonary fibrosis. Immunofluorescent study of one of the biopsy sections with pulmonary fibrosis from a patient with only IgM serum antinuclear factor showed IgM in the alveolar septa. Relatively little fibrosis was present in immunoglobulin-laden areas whereas no immunoglobulin could be demonstrated in the adjacent alveolar septa showing marked fibrosis. Seven out of 10 patients with X-ray evidence of severe interstitial pulmonary fibrosis and typical restrictive ventilatory defects ...
http://annals.org/aim/article-abstract/683344/positive-antinuclear-factor-patients-unexplained-pulmonary-fibrosis
Functional similarities of asbestosis and cryptogenic fibrosing alveolitis
Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. Bernstein, R.M.; Morgan, S.H.; Chapman, J.; Bunn, C.C.; Mathews, M.B.; Turner-Warick, M.; Hughes, G.R.V. // British Medical Journal (Clinical Research Edition);7/21/1984, Vol. 289 Issue 6438, p151 Discusses the function of anti-jo-1 antibody in patients with myositis and cryptogenic fibrosing alveolitis in Great Britain. Definition of myositis; Identification of the antibody by counterimmunoelectrophoresis; Usage of cytotoxic drugs. ...
http://connection.ebscohost.com/c/articles/66060467/functional-similarities-asbestosis-cryptogenic-fibrosing-alveolitis
PRIME PubMed | Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort studPRIME PubMed | Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort stud
PubMed journal article Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort stud were found in PRIME PubMed. Download Prime PubMed App to iPhone or iPad.
https://www.unboundmedicine.com/medline/citation/10619790/full_citation
Abatement of bleomycin-induced increases in vascular permeability, inflammatory cell infiltration, and fibrotic lesions in...
TY - JOUR. T1 - Abatement of bleomycin-induced increases in vascular permeability, inflammatory cell infiltration, and fibrotic lesions in hamster lungs by combined treatment with taurine and niacin. AU - Wang, Q.. AU - Hyde, D. M.. AU - Giri, S. N.. PY - 1992. Y1 - 1992. N2 - BACKGROUND: The bleomycin (BL) hamster model of interstitial pulmonary fibrosis has been widely used to study the pathogenesis of interstitial pulmonary fibrosis and to screen potentially desirable antifibrotic agents. We have recently shown that taurine and niacin in combination, diminished BL- induced increases in lung lipid peroxidation and hydroxyproline content in hamsters. In the present study, we have evaluated the effects of taurine and niacin on the bronchoalveolar lavage (BAL) cells, and morphologic and morphometric features of the lung in the same model of pulmonary fibrosis. EXPERIMENTAL DESIGN: The hamsters were divided into 4 groups: saline; taurine + niacin + saline; BL; and taurine + niacin + BL. Treatment ...
https://ucdavis.pure.elsevier.com/en/publications/abatement-of-bleomycin-induced-increases-in-vascular-permeability
IJMS | Free Full-Text | Fasudil, a Rho-Kinase Inhibitor, Attenuates Bleomycin-Induced Pulmonary Fibrosis in MiceIJMS | Free Full-Text | Fasudil, a Rho-Kinase Inhibitor, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice
The mechanisms underlying the pathogenesis of idiopathic pulmonary fibrosis (IPF) involve multiple pathways, such as inflammation, epithelial mesenchymal transition, coagulation, oxidative stress, and developmental processes. The small GTPase, RhoA, and its target protein, Rho-kinase (ROCK), may interact with other signaling pathways known to contribute to pulmonary fibrosis. This study aimed to determine the beneficial effects and mechanisms of fasudil, a selective ROCK inhibitor, on bleomycin-induced pulmonary fibrosis in mice. Our results showed that the Aschcroft score and hydroxyproline content of the bleomycin-treated mouse lung decreased in response to fasudil treatment. The number of infiltrated inflammatory cells in the bronchoalveolar lavage fluid (BALF) was attenuated by fasudil. In addition, fasudil reduced the production of transforming growth factor-β1 (TGF-β1), connective tissue growth factor (CTGF), alpha-smooth muscle actin (α-SMA), and plasminogen activator inhibitor-1 (PAI-1)
http://www.mdpi.com/1422-0067/13/7/8293/xml
Procurement and Analysis of Specimens From Individuals With Pulmonary Fibrosis - Full Text View - ClinicalTrials.govProcurement and Analysis of Specimens From Individuals With Pulmonary Fibrosis - Full Text View - ClinicalTrials.gov
Individuals who are 18 years of age or older with any of the following:. Idiopathic pulmonary fibrosis (defined by either an open lung biopsy demonstrating pulmonary fibrosis and/or HRCT scan findings consistent with idiopathic pulmonary fibrosis as outlined by the American Thoracic Society/European Respiratory Society guidelines),. Familial pulmonary fibrosis (defined as idiopathic pulmonary fibrosis in two or more first-degree relatives). Relatives of patients with hereditary pulmonary fibrosis,. Hermansky-Pudlak syndrome (diagnosed by paucity or deficiency of platelet dense bodies on whole mount electron microscopy),. Pulmonary fibrosis associated with rheumatoid arthritis [defined by 1987 American College of Rheumatology Revised Criteria for the Classification of RA], or. Healthy research volunteers by history and indicated tests (individuals without history of chronic pulmonary disorder, collagen vascular disease, or bleeding disorder).. EXCLUSION CRITERIA:. Individuals with any of the ...
https://clinicaltrials.gov/ct2/show/NCT00084305
Procurement and Analysis of Specimens From Individuals With Pulmonary Fibrosis - Full Text View - ClinicalTrials.govProcurement and Analysis of Specimens From Individuals With Pulmonary Fibrosis - Full Text View - ClinicalTrials.gov
Individuals who are 18 years of age or older with any of the following:. Idiopathic pulmonary fibrosis (defined by either an open lung biopsy demonstrating pulmonary fibrosis and/or HRCT scan findings consistent with idiopathic pulmonary fibrosis as outlined by the American Thoracic Society/European Respiratory Society guidelines),. Familial pulmonary fibrosis (defined as idiopathic pulmonary fibrosis in two or more first-degree relatives). Relatives of patients with hereditary pulmonary fibrosis,. Hermansky-Pudlak syndrome (diagnosed by paucity or deficiency of platelet dense bodies on whole mount electron microscopy),. Pulmonary fibrosis associated with rheumatoid arthritis [defined by 1987 American College of Rheumatology Revised Criteria for the Classification of RA], or. Healthy research volunteers by history and indicated tests (individuals without history of chronic pulmonary disorder, collagen vascular disease, or bleeding disorder).. EXCLUSION CRITERIA:. Individuals with any of the ...
https://clinicaltrials.gov/ct2/show/NCT00084305?recr=Open&cond=%22Pulmonary+Fibrosis%22&rank=11
Cryptogenic fibrosing alveolitis and lung cancer: the BTS study | ThoraxCryptogenic fibrosing alveolitis and lung cancer: the BTS study | Thorax
The mortality analysis of the members of the BTS CFA cohort identified that there were 46 deaths from lung cancer among 488 people who died (9.4%) and 23 (6.9%) deaths with both idiopathic fibrosing alveolitis and lung cancer mentioned on the death certificates, a figure only marginally higher than the UK co-mortality estimate (5.6%).3. It is plausible that the population-based co-mortality studies2 3 were limited by incomplete listings of pulmonary fibrosis on the death certificates, and diagnostic misclassification may have also contributed to the lack of association between IPF and lung cancer. A far higher prevalence of lung cancer was reported in other studies. The highest were those by Matsushita et al,1 Hironaka and Fukayama6 and Qunn,7 with a lung cancer prevalence of 48.2%, 45.7% and 43.1%, respectively. All of these studies were autopsy studies conducted in Japan and none was blinded. These estimates may be elevated by the increased probability of the presence of lung cancer being ...
https://thorax.bmj.com/content/65/1/70
A new model of progressive pulmonary fibrosis in rats<...
TY - JOUR. T1 - A new model of progressive pulmonary fibrosis in rats. AU - Last, Jerold A. AU - Gelzleichter, T. R.. AU - Pinkerton, Kent E. AU - Walker, R. M.. AU - Witschi, H.. PY - 1993. Y1 - 1993. N2 - Sprague-Dawley rats were exposed for 6 h daily to 0.8 ppm of ozone and 14.4 ppm of nitrogen dioxide. Approximately 7 to 10 wk after the initiation of exposure, animals began to demonstrate respiratory insufficiency and severe weight loss. About half of the rats died between Days 55 and 78 of exposure; no overt ill effects were observed in animals exposed to filtered air, to ozone alone, or to nitrogen dioxide. Biochemical findings in animals exposed to ozone and nitrogen dioxide included increased lung content of DNA, protein, collagen, and elastin, which was about 300% higher than the control values. The collagen-specific crosslink hydroxypyridinium, a biomarker for mature collagen in the lung, was decreased by about 40%. These results are consistent with extensive breakdown and remodeling ...
https://ucdavis.pure.elsevier.com/en/publications/a-new-model-of-progressive-pulmonary-fibrosis-in-rats
Idiopathic Pulmonary Fibrosis. What is Pulmonary Fibrosis? | PatientIdiopathic Pulmonary Fibrosis. What is Pulmonary Fibrosis? | Patient
Synonyms: fibrosing alveolitis, cryptogenic fibrosing alveolitis Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterised initially...
https://patient.info/doctor/Pulmonary-Fibrosis
Antifibrotic effects of CXCR4 antagonist in bleomycin-induced pulmonary fibrosis in mice - 曽根, 三郎 - 論文一覧 - 徳島大学機関リポジトリ
Circulating fibrocytes had been reported to migrate into the injured lungs, and contribute to fibrogenesis via chemokine-chemokine receptor systems including CXCL12-CXCR4 axis. Here we hypothesized that blockade of CXCR4 might inhibit the migration of fibrocytes to the injured lungs and the subsequent pulmonary fibrosis. To explore the antifibrotic effects of blockade of CXCR4, we used a specific antagonist for CXCR4, AMD3100, in bleomycin-induced pulmonary fibrosis model in mice. Administration of AMD3100 significantly improved the loss of body weight of mice treated with bleomycin, and inhibited the fibrotic lesion in subpleural areas of the lungs. The quantitative analysis demonstrated that treatment with AMD3100 reduced the collagen content and fibrotic score (Aschcroft score) in the lungs. Although AMD3100 did not affect cell classification in bronchoalveolar lavage fluid on day 7, the percentage of lymphocytes was reduced by AMD3100 on day 14. AMD3100 directly inhibited the migration of ...
https://repo.lib.tokushima-u.ac.jp/ja/list/author-page/60044/item/106047
Studies of Cxcl12 in Hypoxia-Induced Pulmonary Fibrosis - Taipei Medical University
Chronic lung diseases including asthma and idiopathic pulmonary fibrosis (IPF) are characterized by the airway inflammation, airway remodeling, subepithelial fibrosis, and hypoxia. Previous study indicated that hypoxia plays a critical role in tissue fibrosis. In chronic asthma and IPF, the CXCR4/CXCL12 (stromal cell-derived factor-1, SDF-1) axis plays important role in pulmonary fibrosis. CXCL12 is a potent chemokine for homing of CXCR4+ fibrocytes to sites of lung tissue injury, which directly contribute to pulmonary fibrosis. Circulating CXCR4+ fibrocytes and CXC12 were found to be significantly increases in both plasma and lung of the patient with pulmonary fibrosis. Moreover, an anti-CXCL12 neutralizing antibody attenuated bleomycin-induced pulmonary fibrosis in mice. In addition, CXCL12 plays an important role in carcinoma-associated fibroblast differentiation. These results suggest that interfering with CXCL12 network may help to block pulmonary fibrosis. There is increasing evidence ...
https://tmu.pure.elsevier.com/en/projects/studies-of-cxcl12-in-hypoxia-induced-pulmonary-fibrosis-2
Pharmacologic Inhibition of HIF-1α Attenuates Radiation-Induced Pulmonary Fibrosis in a Preclinical Image Guided Radiation...Pharmacologic Inhibition of HIF-1α Attenuates Radiation-Induced Pulmonary Fibrosis in a Preclinical Image Guided Radiation...
TY - JOUR. T1 - Pharmacologic Inhibition of HIF-1α Attenuates Radiation-Induced Pulmonary Fibrosis in a Preclinical Image Guided Radiation Therapy. AU - Nam, Jae Kyung. AU - Kim, A. Ram. AU - Choi, Seo Hyun. AU - Kim, Ji Hee. AU - Han, Su Chul. AU - Park, Seungwoo. AU - Lee, Yong Jin. AU - Kim, Joon. AU - Cho, Jaeho. AU - Lee, Hae June. AU - Lee, Yoon Jin. N1 - Funding Information: This work was supported by grants from the National Research Foundation ( NRF-2017M2A2A7A02019482/2020M2D9A2093964 and NRF-2020R1A2B5B02002709 ), and a grant from the Korea Institute of Radiologic and Medical Sciences (KIRAMS, 50531-2020 ) funded by the Ministry of Science and ICT (MSIT), Republic of Korea. PY - 2021/2/1. Y1 - 2021/2/1. N2 - Purpose: Radiation-induced pulmonary fibrosis (RIPF) is a long-term side effect of thoracic radiation therapy. Hypoxia-induced vascular endothelial mesenchymal transition (EndMT) can occur during the development of RIPF. Here, we examined the direct contribution of endothelial ...
https://yonsei.pure.elsevier.com/en/publications/pharmacologic-inhibition-of-hif-1%CE%B1-attenuates-radiation-induced-p
Toll-like receptor 4 promotes fibrosis in bleomycin-induced lung injury in mice | GMR | Genetics and Molecular Research | The...Toll-like receptor 4 promotes fibrosis in bleomycin-induced lung injury in mice | GMR | Genetics and Molecular Research | The...
The specific role of Toll-like receptor 4 (TLR4) in bleomycin-induced lung fibrosis of mice, a model of human idiopathic pulmonary fibrosis, has not been characterized. We injected bleomycin intratracheally into TLR4 knockout (TLR4-/-) and wild-type (WT) mice. Twenty-one days after injection, mice were sacrificed and their lungs were harvested for pathological, hydroxyproline, mRNA expression, and collagen I analyses. Body weight changes and mortality were observed.
https://geneticsmr.com/articles/5743
Treatment of idiopathic pulmonary fibrosisTreatment of idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF, also called cryptogenic fibrosing alveolitis) is specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause, occurring in adults and limited to the lungs. It is associated with the his
https://www.uptodate.com/contents/treatment-of-idiopathic-pulmonary-fibrosis
Pulmonary Fibrosis Symptoms | Get Latest Health Slideshow on Pulmonary Fibrosis SymptomsPulmonary Fibrosis Symptoms | Get Latest Health Slideshow on Pulmonary Fibrosis Symptoms
Pulmonary Fibrosis Symptoms Slideshows: Get information on Pulmonary Fibrosis Symptoms. See Slideshows and learn about all the facts related to Pulmonary Fibrosis Symptoms from our health website Onlymyhealth.com.
https://www.onlymyhealth.com/search_pulmonary-fibrosis-symptoms_Slideshow.html
Pathogenesis of idiopathic pulmonary fibrosisPathogenesis of idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF), previously known as cryptogenic fibrosing alveolitis (CFA) in Europe, is a chronic, relentlessly progressive fibrotic disorder of the lower respiratory tract that typically affects adults over the age of 40. Idiop
https://www.uptodate.com/contents/pathogenesis-of-idiopathic-pulmonary-fibrosis
Role of fibronectin in fibrotic lung disease. A growth factor for human lung fibroblasts<...
TY - JOUR. T1 - Role of fibronectin in fibrotic lung disease. A growth factor for human lung fibroblasts. AU - Bitterman, P.. AU - Rennard, S.. AU - Adelberg, S.. AU - Crystal, R. G.. PY - 1983. Y1 - 1983. N2 - The presence of increased amounts of the matrix component fibronectin together with alveolar macrophage-derived growth factor within the alveolar structures of patients with fibrotic lung disease may play a significant role in the fibrosis characteristic of these disorders, by amplifying the numbers of fibroblasts in the alveolar structures of these patients.. AB - The presence of increased amounts of the matrix component fibronectin together with alveolar macrophage-derived growth factor within the alveolar structures of patients with fibrotic lung disease may play a significant role in the fibrosis characteristic of these disorders, by amplifying the numbers of fibroblasts in the alveolar structures of these patients.. UR - ...
https://experts.nebraska.edu/en/publications/role-of-fibronectin-in-fibrotic-lung-disease-a-growth-factor-for-
What Does Pulmonary Fibrosis Mean? - Healthtopquestions - HTQ
Pulmonary fibrosis may be a secondary effect of other diseases. Most of these are classified as interstitial lung diseases. Examples include autoimmune disorders, viral infections and bacterial infection like tuberculosis which may cause fibrotic changes in both lungs upper or lower lobes and other microscopic injuries to the lung. However, pulmonary fibrosis can also appear without any known cause. In this case, it is termed idiopathic. Most idiopathic cases are diagnosed as idiopathic pulmonary fibrosis. This is a diagnosis of exclusion of a characteristic set of histologic/pathologic features known as usual interstitial pneumonia (UIP). In either case, there is a growing body of evidence which points to a genetic predisposition in a subset of patients. For example, a mutation in surfactant protein C (SP-C) has been found to exist in some families with a history of pulmonary fibrosis. Autosomal dominant mutations in the TERC or TERT genes, which encode telomerase, have been identified in ...
https://qa.healthtopquestions.com/24441/what-does-pulmonary-fibrosis-mean
Executive Director - Canadian Pulmonary Fibrosis FoundationExecutive Director - Canadian Pulmonary Fibrosis Foundation
Canadian Pulmonary Fibrosis Foundation (CPFF) seeks an Executive Director who is passionate, mission-driven and a self-directed individual. The ideal candidate has experience in the nonprofit sector, has excellent relationship and management skills, is innovative and effective in fundraising, has prior experience working with a volunteer Board of Directors, and can develop and execute a vision for CPFF.. CPFF is a national patient-led and patient-focused organization dedicated to the needs of pulmonary fibrosis patients, their families, caregivers, and health care professionals. CPFF is recognized globally for being a leader in pulmonary fibrosis awareness and advocacy.. CPFFs mission includes patient and caregiver support and education, public education about pulmonary fibrosis and support for pulmonary fibrosis research. It works closely with the Medical Advisory Board comprised of some of Canadas top respirologists and with a network of sponsors and partners. Over the past seven years the ...
http://cpff.ca/about-cpff/executive-director/
Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis | JEMInhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis | JEM
Here, we show the pivotal role of PDGF signaling in the pathogenesis of radiation-induced pulmonary fibrosis. Importantly, our findings suggest that direct inhibition of fibrogenesis by PDGF RTKIs is an effective strategy to attenuate lung fibrosis. We found that three distinct inhibitors of PDGF signaling (Imatinib/Gleevec, SU9518, and SU11657) markedly attenuated pulmonary fibrosis in a mouse model of radiation-induced lung fibrosis (C57/Bl6).. We could demonstrate that treatment of irradiated mice with PDGF RTKIs markedly attenuates the development of fibroblast foci, the hallmark of pulmonary fibrosis, and the subsequent remodeling of the lung architecture. The morphological results were in agreement with qualitative and quantitative high resolution CT scans of mouse lungs, demonstrating that PDGFR inhibition could dramatically attenuate the typical radiological features of lung fibrosis induced by thoracic irradiation.. Interestingly, with respect to the time course of fibrosis development, ...
http://jem.rupress.org/content/201/6/925
pulmonary fibrosis treatment marketpulmonary fibrosis treatment market
A recent market study published by the company Pulmonary Fibrosis Treatment Market: Global Industry Analysis 2014-2018 & Forecast, 2019-2029 consists of a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historic as well as current growth parameters of the pulmonary fibrosis treatment market, the growth prospects of the market can be obtained with maximum precision. The report features the unique and salient factors that are likely to significantly impact the development of the pulmonary fibrosis treatment market during the forecast period. It can help market players modify their manufacturing and marketing strategies to envisage maximum growth in the pulmonary fibrosis treatment market in the upcoming years. The report provides detailed information about the current and future growth prospects of the pulmonary fibrosis treatment market in the most comprehensive manner for the better understanding of readers.. Chapter 01 - Executive ...
https://www.persistencemarketresearch.com/market-research/pulmonary-fibrosis-treatment-market.asp
Jo 1 Antibodies, IgG, Serum - Mayo Medical Laboratories | Pediatric Catalog
Jo 1 (histidyl tRNA synthetase) is a member of the amino acyl-tRNA synthetase family of enzymes found in all nucleated cells. Jo 1 antibodies in patients with polymyositis bind to conformational epitopes of the enzyme protein and inhibit its catalytic activity in vitro.(1). Jo 1 antibodies are a marker for the disease polymyositis, and occur most commonly in myositis patients who also have interstitial lung disease. The antibodies occur in up to 50% of patients with interstitial pulmonary fibrosis and symmetrical polyarthritis.(2). See Connective Tissue Disease Cascade (CTDC) in Special Instructions.. ...
http://pediatric.testcatalog.org/show/JO1
Jo 1 Antibodies, IgG, Serum - Wyoming Medical Center
Jo 1 (histidyl tRNA synthetase) is a member of the amino acyl-tRNA synthetase family of enzymes found in all nucleated cells. Jo 1 antibodies in patients with polymyositis bind to conformational epitopes of the enzyme protein and inhibit its catalytic activity in vitro.(1). Jo 1 antibodies are a marker for the disease polymyositis, and occur most commonly in myositis patients who also have interstitial lung disease. The antibodies occur in up to 50% of patients with interstitial pulmonary fibrosis and symmetrical polyarthritis.(2). See Connective Tissue Disease Cascade (CTDC) in Special Instructions.. ...
http://wyomingmedicalcenter.testcatalog.org/show/JO1
How many people with idiopathic pulmonary fibrosis are on lipitor (or related anti-cholesterol?How many people with idiopathic pulmonary fibrosis are on lipitor (or related anti-cholesterol?
1 Answer - Posted in: lipitor, idiopathic pulmonary fibrosis - Answer: Havent heard that before, but that doesnt mean anything at all. My ...
https://www.drugs.com/answers/many-people-idiopathic-pulmonary-fibrosis-lipitor-529390.html
Feifukang ameliorates pulmonary fibrosis by inhibiting JAK-STAT signaling pathway | BMC Complementary Medicine and Therapies |...Feifukang ameliorates pulmonary fibrosis by inhibiting JAK-STAT signaling pathway | BMC Complementary Medicine and Therapies |...
Feifukang (FFK) is a traditional Chinese medicine composed of herbs that protect lung function. However, difficulty arises regarding the clinical application of FFK due to the complex mechanism of Chinese medicines. This study aimed to investigate the efficacy of FFK and explore its targeted genes and pathways. Histopathological changes and collagen deposition were measured to evaluate the effect of FFK on bleomycin-induced pulmonary fibrosis in mice. The differentially expressed targeted genes and pathways were first screened using RNA sequencing. Then network pharmacology and other experiments were conducted to confirm RNA sequencing data. FFK treatment reduced the pathological score and collagen deposition, with a decrease in α-SMA and collagen. RNA sequencing and network pharmacology results all showed that FFK can ameliorate pulmonary fibrosis through multi-genes and multi-pathways. The targeted genes in JAK-STAT signaling pathway are some of the most notable components of these multi-genes and
https://bmccomplementmedtherapies.biomedcentral.com/articles/10.1186/s12906-018-2297-3/figures/5
Goulet Needs Lung Transplant | Who2Goulet Needs Lung Transplant | Who2
Singer Robert Goulet is gravely ill at the sickbay to the stars, Cedars-Sinai Medical Center in Los Angeles.Goulets family says he has Interstitial Pulmonary Fibrosis, a rare but rapidly progressive and fatal condition. Goulet is hoping for a lung transplant if a donor can be found.
https://www.who2.com/goulet-needs-lung-transplant/
The Eagle Eye News: Loving care of five daughters proved as a miracleThe Eagle Eye News: Loving care of five daughters proved as a miracle
Ludhiana, 6th April, 2012 (Shalu Arora and Rector Kathuria) Mrs Amrit Kaur-a 65 year old lady - W/o S. Gurcharan Singh of Janakpuri was in a serious condition. She had developed a large clot in her left leg which was in imminent danger of getting loose and blocking her lungs. She was seen in the Emergency by Dr Harinder Singh Bedi - head of Cardio Vascular Endovascular & Thoracic Surgery at the Christian Medical College & Hospital in Ludhiana. On examination and investigation Dr Bedi found that she already had previous episodes of pulmonary embolism. As it is - she suffered from a lung disease called Interstitial Pulmonary Fibrosis for which she was already under treatment. Her lung functions were very low because of the ILD and any further pulmonary embolism would have been potentially fatal. After a thorough check up she underwent a new procedure called catheter directed thrombolysis (CDT) with a strong blood thinner - tissue plasminogen activator (TPA) . Dr Bedi explained that this clot ...
http://theeagleeyenews.blogspot.com/2012/04/loving-care-of-five-daughters-proved-as.html
Familial Pulmonary Fibrosis | Pulmonary Fibrosis FoundationFamilial Pulmonary Fibrosis | Pulmonary Fibrosis Foundation
Familial Pulmonary Fibrosis webinar presented by Janet Talbert, MS, CGC, Advisory for the National Jewish Health Interstitial Lung Disease Program. View the entire full length webinar here today. Please contact us for further detail!
https://www.pulmonaryfibrosis.org/life-with-pf/pff-educational-resources/webinars/familial-pulmonary-fibrosis
Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. |...Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. |...
Idiopathic pulmonary fibrosis is an inexorably fatal disorder characterized by connective tissue deposition within the terminal air spaces resulting in loss of lung function and eventual respiratory failure. Previously, we demonstrated that foci of activated fibroblasts expressing high levels of fibronectin, procollagen, and smooth muscle actin and thus resembling those found in healing wounds are responsible for the connective tissue deposition and scarring in idiopathic pulmonary fibrosis. Using in situ hybridization and immunohistochemistry, we now demonstrate the presence of transforming growth factor beta 1 (TGF-beta 1), a potent profibrotic cytokine, in the foci containing these activated fibroblasts. These results suggest that matrix-associated TGF-beta 1 may serve as a stimulus for the persistent expression of connective tissue genes. One potential source of the TGF-beta 1 is the alveolar macrophage, and we demonstrate the expression of abundant TGF-beta 1 mRNA in alveolar macrophages in ...
https://www.pnas.org/content/88/15/6642?ijkey=9fc78979c3adceaf841ff66ee79de6e0c23338c2&keytype2=tf_ipsecsha
Familial Pulmonary Fibrosis Genetic Counseling ProgramFamilial Pulmonary Fibrosis Genetic Counseling Program
About the Familial Pulmonary Fibrosis Genetic Counseling Program and the affiliation between National Jewish and the Coalition for Pulmonary Fibrosis.
https://www.nationaljewish.org/directory/fpf-genetic-counseling
Pulmonary Fibrosis Patient Stories | Life With Pulmonary FibrosisPulmonary Fibrosis Patient Stories | Life With Pulmonary Fibrosis
Patients with Pulmonary Fibrosis are not alone. Watch inspiring stories of those living with Pulmonary Fibrosis, including their challenges and triumphs, here.
https://www.lifewithpulmonaryfibrosis.com/patient-stories
Pulmonary fibrosis: Signs, Indications, Symptoms, Causes, Treatment, Therapy, PreventionPulmonary fibrosis: Signs, Indications, Symptoms, Causes, Treatment, Therapy, Prevention
Pulmonary fibrosis is more prevalent among men than it is among women. Adults between the ages of 40 and 70 have the highest risk, and approximately 65% of those affected by the condition are over the age of 60. Certain chemotherapy drugs and cardiac medications are potential risk factors, and these drugs are most commonly used by individuals in this age category. Some medical researchers believe that pulmonary fibrosis may begin as an inflammatory response. In tissues like the lungs that dont have the capacity to regenerate, inflammation can lead to scarring. Scar tissue cant support specialized cells, so functional impairment occurs. This theory appears to be supported by the fact that pulmonary fibrosis often arises in conjunction with autoimmune diseases like lupus erythematosus, rheumatoid arthritis, and scleroderma. There are also higher incidences of pulmonary fibrosis among individuals whove been exposed to environmental toxicants like cigarette smoke, asbestos fibers, radiation, and ...
http://medlexi.com/Pulmonary_fibrosis
A promoter SNP rs4073T|A in the common allele of the interleukin 8 gene is associated with the development of idiopathic...A promoter SNP rs4073T|A in the common allele of the interleukin 8 gene is associated with the development of idiopathic...
Interleukin-8 (IL-8) is a potent chemo-attractant cytokine responsible for neutrophil infiltration in lungs with idiopathic pulmonary fibrosis (IPF). The IL-8 protein and mRNA expression are increased in the lung with IPF. We evaluated the effect of single nucleotide polymorphisms (SNPs) of the IL-8 gene on the risk of IPF. One promoter (rs4073T>A) and two intronic SNPs (rs2227307T>G and rs2227306C>T) of the IL-8 genes were genotyped in 237 subjects with IPF and 456 normal controls. Logistic regression analysis was applied to evaluate the association of these SNPs with IPF. IL-8 in BAL fluids was measured using a quantitative sandwich enzyme immunoassay, and promoter activity was assessed using the luciferase reporter assay. The minor allele frequencies of rs4073T>A and rs2227307T>G were significantly lower in the 162 subjects with surgical biopsy-proven IPF and 75 subjects with clinical IPF compared with normal controls in the recessive model (OR = 0.46 and 0.48, p = 0.006 and 0.007, respectively). The
https://respiratory-research.biomedcentral.com/articles/10.1186/1465-9921-12-73
Protection from Pulmonary Fibrosis in the Absence of CCR2 Signaling | The Journal of ImmunologyProtection from Pulmonary Fibrosis in the Absence of CCR2 Signaling | The Journal of Immunology
Our studies demonstrate that signaling via the CCR2 receptor leads to the generation of pro-fibrotic signals following FITC or bleomycin inoculation. In particular, our studies yield several important points: 1) in the absence of CCR2, FITC-induced pulmonary fibrosis is diminished both histologically and quantitatively; 2) the protection is related to the absence of this specific chemokine receptor; deletion of the CCR5 receptor had no effect on the severity of pulmonary fibrosis; 3) the protection conferred by the absence of CCR2 is a generalized phenomenon; CCR2−/− mice are protected from pulmonary fibrosis induced by either FITC or bleomycin; 4) the protection from pulmonary fibrosis seen in CCR2−/− mice is not due to differences in early lung injury caused by the FITC inoculation; 5) despite the absence of the CCR2 receptor, CCR2−/− mice develop an inflammatory cellular response following FITC inoculation that is similar in magnitude and composition compared with the response in ...
http://www.jimmunol.org/content/167/8/4368.long
Whats Happening - Canadian Pulmonary Fibrosis FoundationWhats Happening - Canadian Pulmonary Fibrosis Foundation
Despite the restrictions of the pandemic, this years virtual Pulmonary Fibrosis Awareness Month campaign raised more than $73,000 (as of December 5,2020) and drew thousands to our education forums, Virtual Bubbles event and the Clarke Walk for Pulmonary Fibrosis.. Thanks to all of you, participation and connections were made across the country. More than 500 of you shared tributes and stories and almost 1,100 photos. You walked 16, 107 km, well beyond a return journey across the country (which is 6,818 km one way) in the Clarke Walk for Pulmonary Fibrosis.. Thousands of you took part in our Virtual Bubbles event. And we all appreciated the more than 20 experts from across the country who shared their knowledge and answered your questions during 16 live, online, educational forums.. The Wrap up and Applause event was both touching and inspirational. To the hundreds of people across the country who helped show people with pulmonary fibrosis and their families that they are not alone, thank ...
https://cpff.ca/whats-happening/
Pulmonary Fibrosis Support Group - WellSpan HealthPulmonary Fibrosis Support Group - WellSpan Health
Participants can build a network of support, learn more about Pulmonary Fibrosis, receive practical information on living with the disease, and share common experiences. This support group is open to anyone dealing with Pulmonary Fibrosis and their care partners.. This months topic is Update on Research for Pulmonary Fibrosis by Rebecca Bascom, MD, MPH from Hershey Medical Center Pulmonary Fibrosis Clinic. No registration is necessary. For more information, call (717) 262-8447.. ...
https://www.wellspan.org/events/details/Pulmonary-Fibrosis-Support-Group/955
Reduced activity of transcription factor plays key role in triggering pulmonary fibrosis - Medicalnewser.comReduced activity of transcription factor plays key role in triggering pulmonary fibrosis - Medicalnewser.com
December 26, 2017. To date, the molecular basis of pulmonary fibrosis has been poorly understood. Scientists from the Max Planck Institute for Heart and Lung Research in Bad Nauheim have now shown that reduced activity of the transcription factor FoxO3 plays a key role in the development of the disease. In research on mice, the progress of the disease was able to be halted using drugs that boost FoxO3 activity. The researchers are hoping they may have found a possible approach to treatment.. Idiopathic pulmonary fibrosis is currently an incurable lung disease, in which sufferers lose the ability to absorb adequate oxygen. Although the word idiopathic means that the cause is unknown, the disease primarily affects former and active heavy smokers from the age of 50.. An important role in idiopathic pulmonary fibrosis is played by connective tissue cells called fibroblasts. These cells provide structure to the air sacs (alveoli) in the lungs. During development of the disease, characteristic ...
http://www.medicalnewser.com/2017/12/27/reduced-activity-of-transcription-factor-plays-key-role-in-triggering-pulmonary-fibrosis.html
CGI1746 | Small molecule inhibitors of HCV replicationCGI1746 | Small molecule inhibitors of HCV replication
Background Weve previously explored a therapeutic strategy for specifically targeting the profibrotic activity of IL-13 during experimental pulmonary fibrosis using a fusion protein comprised of human IL-13 and a mutated form of exotoxin A (IL13-PE) and observed that the intranasal delivery of IL13-PE reduced bleomycin-induced pulmonary fibrosis through its elimination of IL-13-responsive cells in the lung. of whole lung samples were performed at day 28 after bleomycin. Intrapulmonary infection promoted a neutralizing IgG2A and IgA antibody response in BALF and serum. Surprisingly, histological analysis showed a prior disease attenuated the introduction of bleomycin-induced pulmonary fibrosis, that was further attenuated from the intranasal administration of IL13-PE modestly. Although prior intranasal administration CGI1746 of IL13-PE didnt elicit an antibody response, the systemic administration of IL13-PE induced a solid neutralizing antibody response. Nevertheless, the last systemic ...
http://lecollege.org/tag/cgi1746/
ISMRM 2015) Longitudinal MRI of Progressive Pulmonary Fibrosis in a Transgenic, TGF-Alpha-Induced Mouse ModelISMRM 2015) Longitudinal MRI of Progressive Pulmonary Fibrosis in a Transgenic, TGF-Alpha-Induced Mouse Model
ability acquisition acute additionally administration alpha animal animals approved arrow arrows aspects assays assess assistance authors available background began biochemical biology black bottom breathing cardiac ceases cell chemical children collection commonly consistent contrast decreased deposition disease display displayed dynamic elucidating epithelial etiology examining excised exhibit expiration extending fibrosis final food formed forming free functional funds gating gene generate generated growth healing heterogeneous histological histology hospital human indicating induced inflammation inflammatory insults intense interplay involve involves known larger lesion limited longitudinal lung lungs matrix mechanisms medical mice mimics model models mouse noninflammatory occur pathological persisted play pleura pleural poorly post prepared previously processes progression progressive promise published pulmonary radiology relevant remodeling report require resolution resolve resolved ...
https://archive.ismrm.org/2015/1453.html
Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab | Annals of...Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab | Annals of...
Several cases of fatal exacerbations of fibrosing alveolitis associated with rheumatoid arthritis after infliximab treatment have recently been reported.1 We report here a case of fatal exacerbation of pulmonary fibrosis after adalimumab treatment in a patient with polyarthritis related to systemic sclerosis (SSc).. The patient, a 74 year old woman, had been diagnosed 5 years previously with severe Raynauds syndrome, sclerodactyly, pulmonary fibrosis, abnormal oesophageal peristalsis, and non-specific antinuclear antibodies (1/100; indirect immunofluorescence on Hep 2 cells). She also had severe distal polyarthritis affecting the wrists, metacarpophalangeal and proximal interphalangeal joints, with demineralisation but no erosion on x ray examination. She tested negative for rheumatoid factor and anti-cyclic citrullinated peptide antibodies. Successive treatments with low dose prednisone associated with methotrexate, leflunomide or azathioprine were ineffective ...
http://ard.bmj.com/content/65/6/834
Study finds cause of pulmonary fibrosis in failure of stem cells that repair lungsStudy finds cause of pulmonary fibrosis in failure of stem cells that repair lungs
The study is a major step toward understanding and one day treating pulmonary fibrosis, which affects about 100,000 people in the U.S. The disease often is called idiopathic pulmonary fibrosis because, in most cases, the cause cannot be found. While the prognosis is unpredictable, patients typically survive only three to five years after diagnosis, according to the U.S. National Library of Medicine.. Pulmonary fibrosis slowly robs patients of breath and finally life, said Paul W. Noble, MD, professor and chair of the Department of Medicine and director of the Womens Guild Lung Institute at Cedars-Sinai. In our study, we identified novel potential pathways to finding treatments for this relentless disease. Noble was the studys principal investigator.. The investigators focused on alveoli, the small air sacs at the ends of lung airways. In the alveoli, oxygen and carbon dioxide are exchanged with blood during respiration. Epithelial cells that line the alveoli also make a substance that ...
http://transplantology.org/en/study-finds-cause-pulmonary-fibrosis-failure-stem-cells-repair-lungs/
JCI Insight - Mesenchymal stromal cell exosomes prevent and revert experimental pulmonary fibrosis through modulation of...JCI Insight - Mesenchymal stromal cell exosomes prevent and revert experimental pulmonary fibrosis through modulation of...
Mesenchymal stromal/stem cell (MSC) therapy has shown promise in experimental models of idiopathic pulmonary fibrosis (IPF). The aim of this study was to test the therapeutic effects of extracellular vesicles produced by human BM MSCs (MEx) in a bleomycin-induced pulmonary fibrosis model and investigate mechanisms of action. Adult C57BL/6 mice were challenged with endotracheal instillation of bleomycin and treated with MEx concurrently, or for reversal models, at day 7 or 21. Experimental groups were assessed at day 7, 14, or 28. Bleomycin-challenged mice presented with severe septal thickening and prominent fibrosis, and this was effectively prevented or reversed by MEx treatment. MEx modulated lung macrophage phenotypes, shifting the proportions of lung proinflammatory/classical and nonclassical monocytes and alveolar macrophages toward the monocyte/macrophage profiles of control mice. A parallel immunomodulatory effect was demonstrated in the BM. Notably, transplantation of MEx-preconditioned ...
https://insight.jci.org/articles/view/128060/figure/2
Pulmonary Fibrosis Center by MedicineNet.comPulmonary Fibrosis Center by MedicineNet.com
Pulmonary fibrosis (scarring throughout the lungs) symptoms are shortness of breath, coughing, and diminished exercise tolerance. Idiopathic pulmonary fibrosis describes a condition in which the cause is unknown. Pulmonary fibrosis has many causes such as exposure to asbestos, infections, lupus, RA, and medication.
https://www.medicinenet.com/pulmonary_fibrosis/index.htm
Triptolide protects against TGF‑β1‑induced pulmonary fibrosis by regulating FAK/calpain signalingTriptolide protects against TGF‑β1‑induced pulmonary fibrosis by regulating FAK/calpain signaling
In the present study, TGF-β1 was used to induce the proliferation of lung fibroblasts and generate an in vitro model of pulmonary fibrosis. In a preliminary experiment, treatment with 50 ng/ml TGF-β1 for 48 h induced the proliferation of lung fibroblasts, indicating that this was a suitable concentration to establish the in vitro model. This model has also been used in foreign and domestic studies (31-33). In addition, as lung fibroblasts are considered to participate in pulmonary inflammation and fibrosis in numerous autoimmune diseases, including rheumatoid arthritis (4,34), the model has also been used to investigate pulmonary fibrosis secondary to numerous other diseases in vitro. The present study suggested that TGF-β1 also induced lung fibroblasts to secrete inflammatory cytokine IL-6 and synthesize ColIα and ColIII, which are among the deposited ECM materials (35). It is likely that in lung tissue affected by pulmonary fibrosis, fibroblasts were affected by inflammation for a long ...
https://www.spandidos-publications.com/10.3892/etm.2019.8127
Idiopathic Pulmonary Fibrosis Market Report with Key Vendors, Driver, Challenges & Trends to 2016-2020 | BusinessIdiopathic Pulmonary Fibrosis Market Report with Key Vendors, Driver, Challenges & Trends to 2016-2020 | Business
Before Its News). Idiopathic Pulmonary Fibrosis Market report 2016-2020 focuses on the major drivers and restraints for the key players. Idiopathic Pulmonary Fibrosis research report also provides granular analysis of the market share, segmentation, revenue forecasts and geographic regions of the market. The Idiopathic Pulmonary Fibrosis market research report is a professional and in-depth study on the current state of Idiopathic Pulmonary Fibrosis Industry.. Analysts forecast the global Idiopathic Pulmonary Fibrosis market to grow at a CAGR of 23.97% during the period 2016-2020.. Browse Detailed TOC, Tables, Figures, Charts and Companies Mentioned in Global Idiopathic Pulmonary Fibrosis market research report @ http://www.360marketupdates.com/global-idiopathic-pulmonary-fibrosis-2016-2020-10289800. The Idiopathic Pulmonary Fibrosis Market research report covers the present scenario and the growth prospects of the global Idiopathic Pulmonary Fibrosis industry for 2016-2020.. Idiopathic ...
http://beforeitsnews.com/business/2016/10/idiopathic-pulmonary-fibrosis-market-report-with-key-vendors-driver-challenges-trends-to-2016-2020-3010373.html
Idiopathic Pulmonary Fibrosis Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast - Himachal Pradesh...
Idiopathic Pulmonary Fibrosis Market. The Idiopathic Pulmonary Fibrosis market is expected to increase during the forecast period owing to the increasing prevalent population of Idiopathic Pulmonary Fibrosis (IPF) patients in the 7MM.. The Idiopathic Pulmonary Fibrosis market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Idiopathic Pulmonary Fibrosis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology. The report gives a thorough detail of Idiopathic Pulmonary Fibrosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. Idiopathic Pulmonary Fibrosis Epidemiology. The ...
http://www.himachalpradeshnewspaper.com/story/81522/idiopathic-pulmonary-fibrosis-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast.html
Idiopathic Pulmonary Fibrosis Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast - Delhi TodayIdiopathic Pulmonary Fibrosis Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast - Delhi Today
Idiopathic Pulmonary Fibrosis Market. The Idiopathic Pulmonary Fibrosis market is expected to increase during the forecast period owing to the increasing prevalent population of Idiopathic Pulmonary Fibrosis (IPF) patients in the 7MM.. The Idiopathic Pulmonary Fibrosis market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Idiopathic Pulmonary Fibrosis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology. The report gives a thorough detail of Idiopathic Pulmonary Fibrosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. Idiopathic Pulmonary Fibrosis Epidemiology. The ...
http://www.delhi-today.com/story/83667/idiopathic-pulmonary-fibrosis-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast.html
Desquamative interstitial pneumonia | Article about desquamative interstitial pneumonia by The Free DictionaryDesquamative interstitial pneumonia | Article about desquamative interstitial pneumonia by The Free Dictionary
Looking for desquamative interstitial pneumonia? Find out information about desquamative interstitial pneumonia. in agriculture, method of treating animals infested with skin parasites such as mites, ticks, and warbles. The animal is dipped into or forced to swim... Explanation of desquamative interstitial pneumonia
http://encyclopedia2.thefreedictionary.com/desquamative+interstitial+pneumonia
Idiopathic pulmonary fibrosis: MedlinePlus GeneticsIdiopathic pulmonary fibrosis: MedlinePlus Genetics
Idiopathic pulmonary fibrosis is a chronic, progressive lung disease. This condition causes scar tissue (fibrosis) to build up in the lungs, which makes the lungs unable to transport oxygen into the bloodstream effectively. The disease usually affects people between the ages of 50 and 70. Idiopathic pulmonary fibrosis belongs to a group of conditions called interstitial lung diseases (also known as ILD), which describes lung diseases that involve inflammation or scarring in the lung.. The most common signs and symptoms of idiopathic pulmonary fibrosis are shortness of breath and a persistent dry, hacking cough. Many affected individuals also experience a loss of appetite and gradual weight loss. Some people with idiopathic pulmonary fibrosis develop widened and rounded tips of the fingers and toes (clubbing) resulting from a shortage of oxygen. These features are relatively nonspecific; not everyone with these health problems has idiopathic pulmonary fibrosis. Other respiratory diseases, some of ...
https://medlineplus.gov/genetics/condition/idiopathic-pulmonary-fibrosis/
Diffuse fibrosing alveolitis | definition of diffuse fibrosing alveolitis by Medical dictionaryDiffuse fibrosing alveolitis | definition of diffuse fibrosing alveolitis by Medical dictionary
Looking for online definition of diffuse fibrosing alveolitis in the Medical Dictionary? diffuse fibrosing alveolitis explanation free. What is diffuse fibrosing alveolitis? Meaning of diffuse fibrosing alveolitis medical term. What does diffuse fibrosing alveolitis mean?
https://medical-dictionary.thefreedictionary.com/diffuse+fibrosing+alveolitis
Resistance of fibrogenic responses to glucocorticoid and 2-methoxyestradiol in bleomycin-induced lung fibrosis in mice. -...Resistance of fibrogenic responses to glucocorticoid and 2-methoxyestradiol in bleomycin-induced lung fibrosis in mice. -...
Bleomycin-induced lung fibrosis in mice reproduces some key features of pulmonary fibrosis in humans including alveolar inflammation, myofibroblast proliferation, and collagen deposition. Glucocorticoids have been used as first-line therapy for the treatment of lung fibrosis, although their clinical efficacy is equivocal. We examined the effect of the glucocorticoid, methylprednisolone (MP), and the estrogen metabolite, 2-methoxyestradiol (2MEO) on bleomycin-induced bronchoalveolar inflammation, fibrosis, and changes in lung function. The characterization of the time-course of the bleomycin-induced fibrosis indicated that lung dry mass and hydroxyproline content showed less variance than histopathological assessment of fibrosis. The bleomycin-induced increases in bronchoalveolar lavage (BAL) fluid cell number and protein levels were not significantly influenced by treatment with either MP (1 mg.(kg body mass)(-1).day(-1), i.p.) or 2MEO (50 mg.(kg body mass)(-1).day(-1), i.p.). Lung fibrosis, ...
https://www.scienceexchange.com/publications/447
Prognostic value of transbronchial lung cryobiopsy for the multidisciplinary diagnosis of idiopathic pulmonary fibrosis: a...Prognostic value of transbronchial lung cryobiopsy for the multidisciplinary diagnosis of idiopathic pulmonary fibrosis: a...
We evaluated 500 consecutive cases, 426 of which were included: 266 had TBLC and 160 had SLB. 189 patients had idiopathic pulmonary fibrosis, 143 had other fibrotic interstitial lung diseases, and 94 had non-fibrotic interstitial lung diseases. Patients undergoing TBLC had more comorbidities and better preserved lung function compared with those undergoing SLB; among patients with a final MDT diagnosis of idiopathic pulmonary fibrosis, patients undergoing TBLC were older, had more comorbidities, and had a different post-biopsy treatment profile than those who received SLB. The distinction between idiopathic pulmonary fibrosis and other interstitial lung diseases made by MDT diagnosis on the basis of TBLC biopsy had clear prognostic significance, with a 5-year transplant-free survival of 68% (95% CI 57-76) in patients with an MDT idiopathic pulmonary fibrosis diagnosis based on TBLC compared with 93% (87-96) in patients without an idiopathic pulmonary fibrosis diagnosis based on TBLC (hazard ...
https://www.physiciansweekly.com/prognostic-value-of-transbronchial-lung-cryobiopsy-for-the-multidisciplinary-diagnosis-of-idiopathic-pulmonary-fibrosis-a-retrospective-validation-study/
Idiopathic pulmonary fibrosis. Causes, symptoms, treatment Idiopathic pulmonary fibrosis
Description of disease Idiopathic pulmonary fibrosis. Treatment Idiopathic pulmonary fibrosis. Symptoms and causes Idiopathic pulmonary fibrosis Prophylaxis Idiopathic pulmonary fibrosis
http://drugster.info/ail/pathography/440/
Real-World Study Analysing Progression and Survival of Idiopathic Pulmonary Fibrosis Patients with Preserved Lung Function on...
Real-World Study Analysing Progression and Survival of Idiopathic Pulmonary Fibrosis Patients with Preserved Lung Function on Antifibrotic Treatment
https://adisjournals.figshare.com/articles/figure/Real-World_Study_Analysing_Progression_and_Survival_of_Idiopathic_Pulmonary_Fibrosis_Patients_with_Preserved_Lung_Function_on_Antifibrotic_Treatment/13034141/1
Background The pathogenesis of pulmonary fibrosis remains poorly understood. therefore theoretically - SRC inhibitor...Background The pathogenesis of pulmonary fibrosis remains poorly understood. therefore theoretically - SRC inhibitor...
Background The pathogenesis of pulmonary fibrosis remains poorly understood. therefore theoretically avoiding ligand-receptor discussion. Frizzled-related proteins (FRZB) was the founding person in this family members [16-18] and verified to bind xWNT8 and antagonize its activity in and versions, including the impact caused by lack of endogenous SFRP1 and FRZB in the bleomycin-induced lung fibrosis model. We display that both and so are upregulated during bleomycin-induced lung fibrosis. to review their powerful profile in the bleomycin-induced pulmonary fibrosis model. and mRNA amounts had been 2 log-scales even more abundant than those of and may not be recognized. amounts were significantly improved at all period factors after bleomycin treatment however, not different between period points (Shape?1C) (2-method ANOVA PBS, 0.05 for period and connections). amounts were considerably and consistently elevated as time passes after bleomycin treatment (2-method ANOVA 0.0001 for bleomycin PBS, and ...
https://saracatinib.info/background-the-pathogenesis-of-pulmonary-fibrosis-remains-poorly-understood-therefore-theoretically/
Global Idiopathic Pulmonary Fibrosis Therapeutic Market Size, Share - Industry Trend and Forecast 2016 - 2024 - BizPR.us | US...
Latest industry research report on: Global Idiopathic Pulmonary Fibrosis Therapeutic Market , Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts. A rare lung disease often terminal, idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease affecting the lung interstitium. Patients diagnosed with IPF suffer an extreme lung deterioration resulting a decline in the lung functioning. IPF causes pulmonary fibrosis, which basically means damaging of the lung tissues. Breathing distress is the most common intricacy involved with idiopathic pulmonary fibrosis.. The cause of idiopathic pulmonary fibrosis still remains unknown, however, it is mostly linked with excessive inhalation of smoke or dust, exposure to unhealthy gases and chemicals and smoking of cigarettes. IPF may also be caused due to genetic predisposition or develop from other lung condition.. Some of the medical conditions, which may develop in a patient with ...
http://bizpr.us/2017/10/31/global-idiopathic-pulmonary-fibrosis-therapeutic-market-size-share-industry-trend-forecast-2016-2024/
Idiopathic pulmonary fibrosis | Article about Idiopathic pulmonary fibrosis by The Free DictionaryIdiopathic pulmonary fibrosis | Article about Idiopathic pulmonary fibrosis by The Free Dictionary
Looking for Idiopathic pulmonary fibrosis? Find out information about Idiopathic pulmonary fibrosis. the formation of an abnormal amount of fibrous tissue in an organ or part as the result of inflammation, irritation, or healing Growth of fibrous connective... Explanation of Idiopathic pulmonary fibrosis
http://encyclopedia2.thefreedictionary.com/Idiopathic+pulmonary+fibrosis
Inhibition of serine palmitoyltransferase delays the onset of radiation-induced pulmonary fibrosis through the negative...
TY - JOUR. T1 - Inhibition of serine palmitoyltransferase delays the onset of radiation-induced pulmonary fibrosis through the negative regulation of sphingosine kinase-1 expression. AU - Gorshkova, Irina. AU - Zhou, Tong. AU - Mathew, Biji. AU - Jacobson, Jeffrey R.. AU - Takekoshi, Daisuke. AU - Bhattacharya, Palash. AU - Smith, Brett. AU - Aydogan, Bulent. AU - Weichselbaum, Ralph R.. AU - Natarajan, Viswanathan. AU - Garcia, Joe G.N.. AU - Berdyshev, Evgeny V.. PY - 2012/8. Y1 - 2012/8. N2 - The enforcement of sphingosine-1-phosphate (S1P) signaling network protects from radiation-induced pneumonitis. We now demonstrate that, in contrast to early postirradiation period, late postirradiation sphingosine kinase-1 (SphK1) and sphingoid base-1-phosphates are associated with radiation-induced pulmonary fibrosis (RIF). Using the mouse model, we demonstrate that RIF is characterized by a marked upregulation of S1P and dihydrosphingosine-1-phosphate (DHS1P) levels in the lung tissue and in ...
https://arizona.pure.elsevier.com/en/publications/inhibition-of-serine-palmitoyltransferase-delays-the-onset-of-rad
Idiopathic Pulmonary Fibrosis (IPF) Market Size & Share | Idiopathic Pulmonary Fibrosis (IPF) Market Research Report, Market...Idiopathic Pulmonary Fibrosis (IPF) Market Size & Share | Idiopathic Pulmonary Fibrosis (IPF) Market Research Report, Market...
Idiopathic Pulmonary Fibrosis (IPF) Market Research Report present a detailed analysis of the market listing Idiopathic Pulmonary Fibrosis (IPF) Epidemiology, Drug therapies and pipeline for study period from 2016-2018.
https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-market-insight-epidemiology-and-market-forecast
Overexpression of Sulf2 in idiopathic pulmonary fibrosis | Lung Tissue Research ConsortiumOverexpression of Sulf2 in idiopathic pulmonary fibrosis | Lung Tissue Research Consortium
Previously, we have shown that heparan sulfate (HS) 6-O-endosulfatase 1 (Sulf1) is a transforming growth factor-β1 (TGF-β1)-responsive gene in normal human lung fibroblasts and functions as a negative feedback regulator of TGF-β1 and that TGF-β1 induces the expression of Sulf1 as well as that of the closely related Sulf2 in a murine model of pulmonary fibrosis. In this study, we focused on the role of Sulf2 in modulating TGF-β1 function and the development of pulmonary fibrosis. We found that Sulf2 mRNA was overexpressed in lung samples from human patients with idiopathic pulmonary fibrosis (IPF), and Sulf2 protein was specifically localized to the hyperplastic type II alveolar epithelial cells (AECs). In vitro, TGF-β1 induced the expression of Sulf2 with accompanied HS 6-O-desulfation in A549 cells, adenocarcinoma cells derived from the type II alveolar epithelium. Using small interference RNA to block Sulf2 expression, we observed a biphasic TGF-β1 response with early enhanced Smad ...
https://ltrcpublic.com/content/overexpression-sulf2-idiopathic-pulmonary-fibrosis
restrictive lung disease
Common intrinsic or interstitial lung diseases include interstitial pulmonary fibrosis, sarcoidosis, and hypersensitivity pneumonitis. The autoimmune (collagen) diseases can affect any joint in the body, including the costochondral and costovertebral joints. Restrictive lung diseases are much less common than asthma; thus, it is not surprising that there are not enough hard data to assess whether such processes increase a divers risk of pulmonary barotrauma. If your lungs cant hold as much air as they used to, you may have a restrictive lung disease. In severe cases, the lung tissue, heart and major vessels may be compromised by the deformity and altered mechanics. The AP and transverse diameters of the chest should increase with inspiration, but do not increase to normal levels in these conditions. Symptoms consist of non-productive cough, wheezing and dyspnea; chest radiography is normal in most cases. This can occur when tissue in the chest wall becomes stiffened, or due to weakened muscles ...
http://trentgreenfamilyfoundation.com/1ayfu7n/d3181b-restrictive-lung-disease
Diagnostic criteria for idiopathic pulmonary fibrosis: A Fleischner Society White Paper<...
TY - JOUR. T1 - Diagnostic criteria for idiopathic pulmonary fibrosis. T2 - A Fleischner Society White Paper. AU - Lynch, David A.. AU - Sverzellati, Nicola. AU - Travis, William D.. AU - Brown, Kevin K.. AU - Colby, Thomas V.. AU - Galvin, Jeffrey R.. AU - Goldin, Jonathan G.. AU - Hansell, David M.. AU - Inoue, Yoshikazu. AU - Johkoh, Takeshi. AU - Nicholson, Andrew G.. AU - Knight, Shandra L.. AU - Raoof, Suhail. AU - Richeldi, Luca. AU - Ryerson, Christopher J.. AU - Ryu, Jay H. AU - Wells, Athol U.. PY - 2017/1/1. Y1 - 2017/1/1. N2 - This Review provides an updated approach to the diagnosis of idiopathic pulmonary fibrosis (IPF), based on a systematic search of the medical literature and the expert opinion of members of the Fleischner Society. A checklist is provided for the clinical evaluation of patients with suspected usual interstitial pneumonia (UIP). The role of CT is expanded to permit diagnosis of IPF without surgical lung biopsy in select cases when CT shows a probable UIP pattern. ...
https://mayoclinic.pure.elsevier.com/en/publications/diagnostic-criteria-for-idiopathic-pulmonary-fibrosis-a-fleischne
Caveolin-1 regulates leucocyte behaviour in fibrotic lung disease | Annals of the Rheumatic DiseasesCaveolin-1 regulates leucocyte behaviour in fibrotic lung disease | Annals of the Rheumatic Diseases
Objectives Reduced caveolin-1 levels in lung fibroblasts from patients with scleroderma and the lungs of bleomycin-treated mice promote collagen overexpression and lung fibrosis. This study was undertaken to determine whether caveolin-1 is deficient in leucocytes from bleomycin-treated mice and patients with scleroderma and to examine the consequences of this deficiency and its reversal.. Methods Mice or cells received the caveolin-1 scaffolding domain (CSD) peptide to reverse the pathological effects of reduced caveolin-1 expression. In bleomycin-treated mice, the levels of caveolin-1 in leucocytes and the effect of CSD peptide on leucocyte accumulation in lung tissue were examined. To validate the results in human disease and to identify caveolin-1-regulated molecular mechanisms, monocytes and neutrophils were isolated from patients with scleroderma and control subjects and caveolin-1, extracellular signal-regulated protein kinase (ERK), c-Jun N-terminal kinase (JNK), p38, CXC chemokine ...
http://ard.bmj.com/content/69/6/1220
Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis is a respiratory disease characterized by the formation of scar tissue in the lungs called fibrosis. IPF patients exhibit a rapid increase in fibrosis leading to severe breathing difficulties, a persistent cough, and difficulty in performing daily tasks. It usually affects people between 50 and 70 years old, particularly men and smokers. The disease is fatal and approximately two-thirds of patients succumb within five years of diagnosis. Most IPF patients die of lung failure while waiting for a lung donor.. IPF is estimated to affect over 130,000 Americans. Every year, 48,000 new cases are diagnosed and 40,000 patients die from the disease. Although there are two FDA-approved therapies for IPF, Esbriet (Roche) and OFEV (Boehringer-Ingelheim), there is no cure.. AEOL 10150 in Idiopathic Pulmonary Fibrosis. Data generated in pre-clinical studies performed under the BARDA contract for Lung-ARS suggest that 10150 may prevent the development of fibrosis in diseases such ...
https://www.aolsrx.com/clinical-data/idiopathic-pulmonary-fibrosis
Idiopathic Pulmonary Fibrosis Market Outlook Report, Epidemiology and Competitive Analysis Report 2030 by DelveInsight - Live...Idiopathic Pulmonary Fibrosis Market Outlook Report, Epidemiology and Competitive Analysis Report 2030 by DelveInsight - Live...
Idiopathic Pulmonary Fibrosis (IPF) is a rare, chronic, progressive fibrosing interstitial pneumonia which is found to affect the middle-aged and older adults; and affects lung tissue (alveoli in particular) by either thickening, stiffening, or persistent and progressive scarring (fibrosis) which increases irreversibly over time. If an individual has IPF, scarring affects the air sacs, limiting the amount of oxygen that gets into the blood. With less oxygen in the blood, one can get breathlessness from everyday activities, like walking. This group of lung disorders is also known as Diffuse Parenchymal Lung Diseases, which is characterized by a broader umbrella of Interstitial Lung Diseases (IDLs).. According to DelveInsight, the total Idiopathic Pulmonary Fibrosis (IPF) prevalent cases in 7 MM was found to be 229,170, in the year 2017.. Request for a detailed sample copy of the report: https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market. Idiopathic Pulmonary ...
http://news.livenewsstockmarket.com/story/288690/idiopathic-pulmonary-fibrosis-market-outlook-report-epidemiology-and-competitive-analysis-report-2030-by-delveinsight.html
Idiopathic Pulmonary Fibrosis Market Outlook Report, Epidemiology and Competitive Analysis Report 2030 by DelveInsight - News...Idiopathic Pulmonary Fibrosis Market Outlook Report, Epidemiology and Competitive Analysis Report 2030 by DelveInsight - News...
Idiopathic Pulmonary Fibrosis (IPF) is a rare, chronic, progressive fibrosing interstitial pneumonia which is found to affect the middle-aged and older adults; and affects lung tissue (alveoli in particular) by either thickening, stiffening, or persistent and progressive scarring (fibrosis) which increases irreversibly over time. If an individual has IPF, scarring affects the air sacs, limiting the amount of oxygen that gets into the blood. With less oxygen in the blood, one can get breathlessness from everyday activities, like walking. This group of lung disorders is also known as Diffuse Parenchymal Lung Diseases, which is characterized by a broader umbrella of Interstitial Lung Diseases (IDLs).. According to DelveInsight, the total Idiopathic Pulmonary Fibrosis (IPF) prevalent cases in 7 MM was found to be 229,170, in the year 2017.. Request for a detailed sample copy of the report: https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market. Idiopathic Pulmonary ...
http://news.newsheadlinesnow.com/story/283762/idiopathic-pulmonary-fibrosis-market-outlook-report-epidemiology-and-competitive-analysis-report-2030-by-delveinsight.html
Idiopathic Pulmonary Fibrosis Market Outlook Report, Epidemiology and Competitive Analysis Report 2030 by DelveInsight -...Idiopathic Pulmonary Fibrosis Market Outlook Report, Epidemiology and Competitive Analysis Report 2030 by DelveInsight -...
Idiopathic Pulmonary Fibrosis (IPF) is a rare, chronic, progressive fibrosing interstitial pneumonia which is found to affect the middle-aged and older adults; and affects lung tissue (alveoli in particular) by either thickening, stiffening, or persistent and progressive scarring (fibrosis) which increases irreversibly over time. If an individual has IPF, scarring affects the air sacs, limiting the amount of oxygen that gets into the blood. With less oxygen in the blood, one can get breathlessness from everyday activities, like walking. This group of lung disorders is also known as Diffuse Parenchymal Lung Diseases, which is characterized by a broader umbrella of Interstitial Lung Diseases (IDLs).. According to DelveInsight, the total Idiopathic Pulmonary Fibrosis (IPF) prevalent cases in 7 MM was found to be 229,170, in the year 2017.. Request for a detailed sample copy of the report: https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market. Idiopathic Pulmonary ...
http://news.wisconsinchronicle.com/story/249389/idiopathic-pulmonary-fibrosis-market-outlook-report-epidemiology-and-competitive-analysis-report-2030-by-delveinsight.html
Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evid | CEPirfenidone in the treatment of idiopathic pulmonary fibrosis: an evid | CE
Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy George A Margaritopoulos,1 Eirini Vasarmidi,2 Katerina M Antoniou2 1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK; 2Department of Thoracic Medicine and Laboratory of Molecular and Cellular Pneumonology, Interstitial Lung Disease Unit, University Hospital of Heraklion, Heraklion, Greece Abstract: The landscape of idiopathic pulmonary fibrosis (IPF) has changed. The significant progress regarding our knowledge on the pathogenesis of the disease together with the experience achieved after a series of negative trials has led to the development of two drugs for the treatment of IPF. Both pirfenidone and nintedanib can slow significantly the rate of disease progression. They are safe with side effects that can be either prevented by close collaboration between health care professionals and patients or treated successfully when they occur, rarely leading to treatment
https://www.dovepress.com/pirfenidone-in-the-treatment-of-idiopathic-pulmonary-fibrosis-an-evide-peer-reviewed-article-CE
Mechanisms of neutrophil accumulation in the lungs of patients with idiopathic pulmonary fibrosis<...
TY - JOUR. T1 - Mechanisms of neutrophil accumulation in the lungs of patients with idiopathic pulmonary fibrosis. AU - Hunninghake, G. W.. AU - Gadek, J. E.. AU - Lawley, T. J.. AU - Crystal, R. G.. PY - 1981/1/1. Y1 - 1981/1/1. N2 - Neutrophils are a characteristic feature of the alveolitis of idiopathic pulmonary fibrosis (IPF), a chronic disorder limited to lung. One mechanism by which neutrophils may be selectively attracted to lung and not other tissues is via the secretion of a neutrophil-specific chemotactic factor by alveolar macrophages. To evaluate the role of alveolar macrophages in modulating the migration of neutrophils to the lung in IPF, alveolar macrophages, obtained by bronchoalveolar lavage of patients with IPF, were evaluated for their ability to release a chemotactic factor for neutrophils. Unstimulated alveolar macrophages from normal individuals did not release the factor. In patients with IPF, there was a significant correlation between the proportions of neutrophils in ...
https://qfrd.pure.elsevier.com/en/publications/mechanisms-of-neutrophil-accumulation-in-the-lungs-of-patients-wi
Article Metrics] Idiopathic pulmonary fibrosis biomarkers: clinical utility and a way o | CBFArticle Metrics] Idiopathic pulmonary fibrosis biomarkers: clinical utility and a way o | CBF
Idiopathic pulmonary fibrosis biomarkers: clinical utility and a way of understanding disease pathogenesis Matthew Flynn, Elisabeth S Baker, Daniel J Kass Dorothy P and Richard P Simmons Center for Interstitial Lung Disease, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA Abstract: Idiopathic pulmonary fibrosis (IPF) is a typically fatal disease that remains incompletely understood despite intense study and the arrival of drugs that may alter the natural history of the disease. Rendering an accurate diagnosis and predicting prognosis remain challenging problems to clinicians. One potential solution to these clinical problems is the identification of IPF biomarkers, easily measured factors that can be employed to predict clinical behavior. Candidate biomarkers have been identified by research in the laboratory on potential culprit cells or genes that may contribute to the pathogenesis of IPF. In this review, we present the current data on a
https://www.dovepress.com/article_metric.php?article_id=21725
Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. - Dr Zarir F. UdwadiaIdiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. - Dr Zarir F. Udwadia
Idiopathic pulmonary fibrosis (IPF), the prototype of interstitial lung diseases, has the worst prognosis and is the only interstitial lung disease for which approved pharmacological treatments are available. Despite being considered a rare disease, IPF patients pose major challenges to both physicians and healthcare systems. It is estimated that a large number of IPF patients reside in BRIC countries (Brazil, Russia, India, and China) given their overall total population of approximately 3 billion inhabitants. Nevertheless, the limited availability of chest imaging in BRIC countries is considered a chief obstacle to diagnosis, since high-resolution computed tomography of the chest is the key diagnostic test for IPF. Further, obtaining reliable lung function tests and providing treatment access is difficult in the more rural areas of these countries. However, IPF might represent an opportunity for BRIC countries: the exponentially increasing demand for the enrollment of IPF patients in clinical ...
https://www.drzarirudwadia.com/idiopathic-pulmonary-fibrosis-in-bric-countries-the-cases-of-brazil-russia-india-and-china/
Idiopathic pulmonary fibrosis: Pathogenesis and management<...
TY - JOUR. T1 - Idiopathic pulmonary fibrosis. T2 - Pathogenesis and management. AU - Sgalla, Giacomo. AU - Iovene, Bruno. AU - Calvello, Mariarosaria. AU - Ori, Margherita. AU - Varone, Francesco. AU - Richeldi, Luca. PY - 2018/2/22. Y1 - 2018/2/22. N2 - Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease characterized by the aberrant accumulation of fibrotic tissue in the lungs parenchyma, associated with significant morbidity and poor prognosis. This review will present the substantial advances achieved in the understanding of IPF pathogenesis and in the therapeutic options that can be offered to patients, and will address the issues regarding diagnosis and management that are still open. Main body: Over the last two decades much has been clarified about the pathogenic pathways underlying the development and progression of the lung scarring in IPF. Sustained alveolar epithelial micro-injury and activation has been recognised as the trigger of several biological ...
https://moh-it.pure.elsevier.com/en/publications/idiopathic-pulmonary-fibrosis-pathogenesis-and-management
Low fat-free mass and body mass index are associated with worse survival in patients with idiopathic pulmonary fibrosis (IPF) -...Low fat-free mass and body mass index are associated with worse survival in patients with idiopathic pulmonary fibrosis (IPF) -...
Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing interstitial lung disease with a poor prognosis. The impact of malnutrition, especialy fat-free mass (FFM), on mortality is scarcely assessed in IPF patients. This study aimed at identifying factors associated with higher mortaliy in IPF. Nutritional status of 185 consecutive IPF patients from a referal Centre were prospectively evaluated by bioelectrical impedancemeter analysis (BIA) to measure FFM, body mass index (BMI), mid-arm circumference, triceps skinfold thickness, food intake analogue visual scale and biology. Malnutrition was defined as a FFM index (FFMI) |15 in women and |17 in men. Stepwise logistic regressions were performed to identify the factors associated with mortality. Malnutrition prevalence was 28% (52/185). IPF patients with low FFMI had higher mortality compared to patients with normal FFMI (p=0.015). In multivariable analyses, factors independently associated with mortality were active cancer, FFMI and BMI.
https://hal-univ-rennes1.archives-ouvertes.fr/hal-02469275
Abstract 12336: Non-invasive Screening for Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis | CirculationAbstract 12336: Non-invasive Screening for Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis | Circulation
Introduction: Pulmonaryhypertension (PH) is a common complication of idiopathic pulmonary fibrosis (IPF) that is associated with poor prognosis. Screening for PH in IPF patients proves to be challenging.. Hypothesis: We hypothesized that combining several non-invasive studies can predict the presence of PH in IPF patients.. Methods: We included 235 IPF patients who underwent right heart catheterization (RHC) as part of the lung transplant evaluation. We measured ECG and echocardiographic variables as well as the pulmonary artery (PA) diameter and ascending aorta (AA) diameters on chest CT. We recorded results of arterial blood gases (ABG), pulmonary function (PFT) and 6-min walk tests (6MWT).. Results: Several variables were predictors of PH in IPF patients in univariate models including arterial oxygenation, 6MWT distance, worse right ventricular (RV) function, the QRS axis, FVC/DLCOc ratio, PA/AA diameter ratio and estimated RV systolic pressure. In multivariate analysis, RV function and PA/AA ...
http://circ.ahajournals.org/content/132/Suppl_3/A12336
The impact of trastuzumab on radiation-induced pulmonary fibrosis: results of an experimental study | AVESİS
There are no data regarding the late toxicity of trastuzumab (T) administration with radiotherapy (RT). In this experimental study, we aimed to asses if concurrent or sequential administration of T has any impact for the development of radiation-induced pulmonary fibrosis in rats. Fifty-four female Wistar-albino rats were divided into 6 groups. First group of rats (Group 1; concurrent T) had irradiation to whole thoracic region concurrently with T. Second group (Group 2: sequential T-RT) received thoracic irradiation, 1 week after T. Third group (Group 3: sequential RT-T) had thoracic irradiation first and they had T injection 1 week after RT. Fourth group (Group 4: T only) had only T application. Fifth group (Group 5: RT) had only RT. The last group (Group 6: sham) of rats were observed without any application. A single dose of 12 Gy was given to both lungs with an anterior field at 2 cm depth. T dose which was equivalent to 6 mg/kg adult dose was calculated for each rat, and injected by the ...
https://avesis.acibadem.edu.tr/yayin/91e3c4cb-52fc-4fb5-a9e0-42c0990c2ade/the-impact-of-trastuzumab-on-radiation-induced-pulmonary-fibrosis-results-of-an-experimental-study
Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosis (IPF)
The term idiopathic means unknown, making it a good name for a disorder that many are unfamiliar with. Its also unclear why idiopathic pulmonary fibrosis (IPF) develops. Idiopathic Pulmonary Fibrosis (IPF) is a disease of the lungs that causes stiffness of the tissue of the lungs. This makes it harder for you to natur
https://www.bluezoneinnergy.com/post/idiopathic-pulmonary-fibrosis-ipf
European Idiopathic Pulmonary Fibrosis & Related Disorders Federation (EU-IPFF)
Brussels, Belgium, 22 February 2016 - Patient groups from nine European countries have come together to establish the European Idiopathic Pulmonary Fibrosis & Related Disorders Federation (EU-IPFF) in order to defend the interests of European patients with idiopathic pulmonary fibrosis (IPF) through one unified voice. IPF is a progressive, irreversible chronic disease of the lungs,1 with currently no known cure. EU-IPFF will push forward the IPF agenda at European level by improving patient access to treatment, increasing disease awareness, and advocating for research into new treatment options.. The newly formed federation represents an important landmark for the independent IPF patient groups and is the culmination of their continued fruitful collaboration building on initiatives like the IPF World Week Awareness Campaign and the IPF Patient Charter (www.ipfcharter.org). EU-IPFF will continue to collaborate with relevant medical organisations and bodies to ensure that the Charter ...
http://ipfworld.org/7-news/102-european-idiopathic-pulmonary-fibrosis-related-disorders-federation-eu-ipff.html
IPF (idiopathic pulmonary fibrosis) Medicine - IPF (idiopathic pulmonary fibrosis) Medicine Exporter, Distributor & Supplier,...
MODERN TIMES HELP LINE PHARMA - Exporter, Distributor & Supplier of IPF (idiopathic pulmonary fibrosis) Medicine based in Delhi, India
http://www.moderntimeshelplinepharma.co.in/ipf-idiopathic-pulmonary-fibrosis-medicine-3240676.html
Correspondence] New guideline for idiopathic pulmonary fibrosis - doctorportal | doctorportal
The Lancet Editors (July 25, p 312)1 highlight the publication of a new international clinical guideline for the treatment of idiopathic pulmonary fibrosis.2 This updated guideline provides conditional recommendations for use of nintedanib and pirfenidone to treat patients with idiopathic pulmonary fibrosis and emphasises the role of individual patients preferences and values in treatment decisions.2 According to the Editors, this guideline suggests that nintedanib and pirfenidone might be suitable for some patients, whereas the conditional recommendation, according to the guideline, is when the majority of individuals in this situation would want the suggested course of action, but many would not.. ...
https://www.doctorportal.com.au/correspondence-new-guideline-for-idiopathic-pulmonary-fibrosis/
What is the diagnosis of Idiopathic Pulmonary Fibrosis? | Idiopathic Pulmonary Fibrosis Diagnosis and PrognosisWhat is the diagnosis of Idiopathic Pulmonary Fibrosis? | Idiopathic Pulmonary Fibrosis Diagnosis and Prognosis
Doctor will diagnose idiopathic pulmonary fibrosis based on your medical history, a physical exam, and the results from tests. Tests can help rule out other causes of your symptoms and show how badly your lungs are damaged.
http://www.onlymyhealth.com/what-diagnosis-idiopathic-pulmonary-fibrosis-12977602579
Action for Pulmonary Fibrosis
We are a charity that focuses on supporting those with pulmonary fibrosis and IPF. We educate healthcare professionals about pulmonary fibrosis and IPF, give funds towards research and set up pulmonary fibrosis support groups. You can read more about symptoms of IPF and pulmonary fibrosis, fundraising for charity and where to find help about diagnosis.
http://www.actionpulmonaryfibrosis.org
Nice | Idiopathic pulmonary fibrosis - NASGPNice | Idiopathic pulmonary fibrosis - NASGP
This guideline is mainly useful to us in terms of when to consider Idiopathic Pulmonary Fibrosis , but there was some information in here that I was not aware of that is important. When to consider Idiopathic Pulmonary Fibrosis: • Patients over age 45 • Persistent breathlessness on exertion •…
https://www.nasgp.org.uk/resource/nice-idiopathic-pulmonary-fibrosis/
Contemporary Approaches To Idiopathic Pulmonary Fibrosis Books Full PDF, ePub, Online
Books contemporary approaches to idiopathic pulmonary fibrosis full online in PDF, ePub format, this books, Books contemporary approaches to idiopathic pulmonary fibrosis in PDF, ePub format. ...
http://www.hitbooks4free.com/books/title/contemporary-approaches-to-idiopathic-pulmonary-fibrosis.html
Effects of Ma-Xing-Shi-Gan-Tang on Bleomycin- Induced Lung Fibrosis in Rats | NCHU Institution RepositoryEffects of Ma-Xing-Shi-Gan-Tang on Bleomycin- Induced Lung Fibrosis in Rats | NCHU Institution Repository
In this study, after doses of 1 g/kg/day of the traditional Chinese formula Ma-Xing-Shi-Gan-Tang (MXSGT), significant reversal of pneumatocysts was achieved in Spague-Dawley rats with bleomycin-induced lung fibrosis. We found that MXSGT can improve the damaged condition of general cellular membranes. Greatly increased levels of lung NO were found in the bleomycin-induced group, which were then significantly reduced by MXSGT. MXSGT drastically prevented depletion of superoxide dismutase (SOD) and reduced the myeloperoxidase (MPO) activities and malondialdehyde (MDA) levels in lung tissue of rats treated with bleomycin. On the basis of the results presented in this paper, MXSGT prevents bleomycin-induced lung fibrosis, and the mechanism may be due to the inhibitory effect on nitric oxide generation in the bleomycin-induced lung-fibrosis model of rats ...
https://ir.lib.nchu.edu.tw/handle/11455/69942
β-Arrestin Deficiency Protects Against Pulmonary Fibrosis in Mice and Prevents Fibroblast Invasion of Extracellular Matrix |...β-Arrestin Deficiency Protects Against Pulmonary Fibrosis in Mice and Prevents Fibroblast Invasion of Extracellular Matrix |...
Idiopathic pulmonary fibrosis is a progressive disease that causes unremitting extracellular matrix deposition with resulting distortion of pulmonary architecture and impaired gas exchange. β-Arrestins regulate G protein (heterotrimeric guanine nucleotide-binding protein)-coupled receptors through receptor desensitization while also acting as signaling scaffolds to facilitate numerous effector pathways. Here, we examine the role of β-arrestin1 and β-arrestin2 in the pathobiology of pulmonary fibrosis. In the bleomycin-induced mouse lung fibrosis model, loss of either β-arrestin1 or β-arrestin2 resulted in protection from mortality, inhibition of matrix deposition, and protected lung function. Fibrosis was prevented despite preserved recruitment of inflammatory cells and fibroblast chemotaxis. However, isolated lung fibroblasts from bleomycin-treated β-arrestin-null mice failed to invade extracellular matrix and displayed altered expression of genes involved in matrix production and ...
https://stm.sciencemag.org/content/3/74/74ra23
Idiopathic pulmonary fibrosis - Simple English Wikipedia, the free encyclopediaIdiopathic pulmonary fibrosis - Simple English Wikipedia, the free encyclopedia
Idiopathic pulmonary fibrosis (IPF) is a chronic irreversible and fatal disease caused by a progressive decline in lung function.[1][2] The term pulmonary fibrosis means scarring of lung tissue and is the cause of worsening dyspnea (shortness of breath). Fibrosis is usually associated with a poor prognosis.[1][2][3] IPF belongs to a large group of more than 200 lung diseases known as interstitial lung diseases (ILDs), characterized by the involvement of lung interstitium. IPF usually occurs in adults of between 50 and 70 years of age, particularly those with a history of cigarette smoking, and affects more men than women. Treatment to slow down the progression of the disease may include nintedanib or pirfenidone.[4] ...
https://simple.wikipedia.org/wiki/Idiopathic_pulmonary_fibrosis
Pulmonary fibrosisPulmonary fibrosis
"Pulmonary Fibrosis". MedicineNet, Inc. Archived from the original on 19 July 2014. Retrieved 26 July 2014. "Pulmonary fibrosis ... Misdiagnosis is common because, while overall pulmonary fibrosis is not rare, each individual type of pulmonary fibrosis is ... "Pulmonary Fibrosis". medlineplus.gov. Retrieved 20 December 2019. "Pulmonary fibrosis - Symptoms and causes". Mayo Clinic. ... and the resulting stiffness or decreased compliance makes pulmonary fibrosis a restrictive lung disease. Pulmonary fibrosis is ...
https://en.wikipedia.org/wiki/Pulmonary_fibrosis
Idiopathic pulmonary fibrosisIdiopathic pulmonary fibrosis
December 2011). "Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis". Respiratory ... Wikimedia Commons has media related to Idiopathic pulmonary fibrosis. Idiopathic pulmonary fibrosis at Curlie (All articles ... "Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical ... The number of published studies on the role of pulmonary rehabilitation in idiopathic pulmonary fibrosis is small, but most of ...
https://en.wikipedia.org/wiki/Idiopathic_pulmonary_fibrosis
Equine multinodular pulmonary fibrosisEquine multinodular pulmonary fibrosis
... is a chronic lung disease of horses. There is evidence that the disease is caused by ... Poth T, Niedermaier G, Hermanns W (January 2009). "Equine multinodular pulmonary fibrosis in association with an EHV-5 ... Signs of equine multinodular pulmonary fibrosis are mainly weight loss, fever, respiratory distress and depression. ... 2007), there are significant pathomorphological findings in lungs with equine multinodular pulmonary fibrosis. In gross ...
https://en.wikipedia.org/wiki/Equine_multinodular_pulmonary_fibrosis
Combined pulmonary fibrosis and emphysemaCombined pulmonary fibrosis and emphysema
... (CPFE), describes a medical syndrome involving both pulmonary fibrosis and emphysema ... February 2006). "Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity". European Respiratory Journal. ... Wand, O; Kramer, MR (January 2018). "The Syndrome of Combined Pulmonary Fibrosis and Emphysema - CPFE". Harefuah. 157 (1): 28- ... Jankowich, MD; Rounds, SI (January 2012). "Combined pulmonary fibrosis and emphysema syndrome: a review". Chest. 141 (1): 222- ...
https://en.wikipedia.org/wiki/Combined_pulmonary_fibrosis_and_emphysema
Hereditary fibrosing poikiloderma with tendon contractures, myopathy, and pulmonary fibrosisHereditary fibrosing poikiloderma with tendon contractures, myopathy, and pulmonary fibrosis
Hereditary fibrosing poikiloderma with tendon contractures, myopathy and pulmonary fibrosis is a rare genetic syndrome ... The main characteristics of this condition are poikiloderma, tendon contractures and progressive pulmonary fibrosis. Other ... Muscle biopsy shows fibrosis and fatty infiltration. Skin biopsy shows fibrosis and alterations of the elastic network. This ... and pulmonary fibrosis. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, (editors). GeneReview ...
https://en.wikipedia.org/wiki/Hereditary_fibrosing_poikiloderma_with_tendon_contractures,_myopathy,_and_pulmonary_fibrosis
Radiation Fibrosis SyndromeRadiation Fibrosis Syndrome
"Pulmonary fibrosis". Cleveland Clinic. Cleveland Clinic. 2021. Retrieved 2 May 2022. "Idiopathic pulmonary fibrosis". AMBOSS. ... Hematic biometry Imaging tests such as X-rays or tomography Pulmonary function tests Biopsy Pulmonary fibrosis is not currently ... "Síndrome de fibrosis por radiación". OncoLink. Trustees of the University of Pennsylvania. Retrieved 2 May 2022. "Fibrosis ... Radiation fibrosis syndrome is a human illness. It occurs as a result of cell death, and can be caused by radiotherapy. It is ...
https://en.wikipedia.org/wiki/Radiation_Fibrosis_Syndrome
Gene silencingGene silencing
"Pulmonary Fibrosis". Mayo Clinic. Retrieved 13 December 2013. Gurujeyalakshmi G, Giri SN (Sep-Oct 1995). "Molecular mechanisms ... such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis. COPD is characterized by goblet cell hyperplasia and ... As a result, when interferon (IFN)-γ was used to knock down TGF-β, fibrosis of the lungs, caused by damage and scarring to lung ... Rennard SI (November 1999). "Inflammation and repair processes in chronic obstructive pulmonary disease". American Journal of ...
https://en.wikipedia.org/wiki/Gene_silencing
Prostaglandin EP2 receptorProstaglandin EP2 receptor
... in fibroblasts from the lungs of mice with bleomycin-induced pulmonary fibrosis and humans with Idiopathic pulmonary fibrosis ... pulmonary fibrosis; certain forms of malignant disease such as colon cancer including those that arise from Adenomatous ... Butaprost for the treatment of pulmonary fibrosis and certain neurological diseases CP533,536 for the stimulation of bone ... forms of inflammation such NMDA receptor-related neurotoxicity and the rodent model of Bleomycin-induced pulmonary fibrosis. ...
https://en.wikipedia.org/wiki/Prostaglandin_EP2_receptor
2021 in Mexico2021 in Mexico
Cándido Pérez). January 22 José Ángel García, 69-70, actor and television director (La rosa de Guadalupe); pulmonary fibrosis. ... "Fallece el director José Ángel García, padre de Gael García, de fibrosis". EL HERALDO. "Matan al empresario Martín Rodríguez en ...
https://en.wikipedia.org/wiki/2021_in_Mexico
Telomerase RNA componentTelomerase RNA component
Swigris JJ, Brown KK (2018-07-25). Idiopathic pulmonary fibrosis. St. Louis. ISBN 978-0-323-54432-0. OCLC 1053744041. Liu Y, ... GeneReviews/NCBI/NIH/UW entry on Dyskeratosis Congenita GeneReviews/NCBI/NIH/UW entry on Pulmonary Fibrosis, Familial ... Mutations in TERC have been associated with dyskeratosis congenita, idiopathic pulmonary fibrosis, aplastic anemia, and ...
https://en.wikipedia.org/wiki/Telomerase_RNA_component
Integrin beta 6Integrin beta 6
Chronic activation of fibroblasts can result in diseases such as pulmonary fibrosis, where the hardening and thickening of the ... King TE, Pardo A, Selman M (December 2011). "Idiopathic pulmonary fibrosis". Lancet. 378 (9807): 1949-61. doi:10.1016/S0140- ... April 2016). "Reduced Ets Domain-containing Protein Elk1 Promotes Pulmonary Fibrosis via Increased Integrin αvβ6 Expression". ... Thus high αvβ6 expression in fibrosis and cancer is usually associated with a poorer prognosis. Fibrosis occurs in response to ...
https://en.wikipedia.org/wiki/Integrin_beta_6
Robert GouletRobert Goulet
On September 30, 2007, Goulet was hospitalized in Las Vegas, where he was diagnosed with idiopathic pulmonary fibrosis, a rare ... While awaiting a lung transplant, Goulet died from pulmonary fibrosis on the evening of October 30, 2007, at Cedars-Sinai ... "Prominent People Lost to IPF/PF: Robert Goulet". Pulmonary Fibrosis Foundation. Retrieved December 9, 2011. "Robert Goulet-2006 ... Deaths from pulmonary fibrosis, Fellows of the Royal Conservatory of Music, Grammy Award winners, Lost Canadians, Male actors ...
https://en.wikipedia.org/wiki/Robert_Goulet
Equid gammaherpesvirus 5Equid gammaherpesvirus 5
It is thought to be the cause of a chronic lung disease of adult horses; equine multinodular pulmonary fibrosis. "ICTV Taxonomy ... Williams, KJ (March 2014). "Gammaherpesviruses and Pulmonary Fibrosis: Evidence From Humans, Horses, and Rodents". Veterinary ...
https://en.wikipedia.org/wiki/Equid_gammaherpesvirus_5
Side effects of bicalutamideSide effects of bicalutamide
Daba MH, El-Tahir KE, Al-Arifi MN, Gubara OA (June 2004). "Drug-induced pulmonary fibrosis". Saudi Medical Journal. 25 (6): 700 ... Interstitial pneumonitis can progress to pulmonary fibrosis and can be fatal. Interstitial pneumonitis with bicalutamide is ... An assessment done prior to the publication of the aforementioned study estimated the rates of pulmonary toxicity with ...
https://en.wikipedia.org/wiki/Side_effects_of_bicalutamide
Lung transplantationLung transplantation
... idiopathic pulmonary fibrosis; 14% cystic fibrosis; 12% idiopathic (formerly known as "primary") pulmonary hypertension; 5% ... Pulmonary Hypertension: A Patient's Survival Guide 3rd ed. p.134. Pulmonary Hypertension: A Patient's Survival Guide 3rd ed. p ... Lung transplantation, or pulmonary transplantation, is a surgical procedure in which one or both lungs are replaced by lungs ... Pulmonary Hypertension: A Patient's Survival Guide 3rd edition p. 126 Rundle RL (2 January 2003). "New Blood Procedure Helps ...
https://en.wikipedia.org/wiki/Lung_transplantation
Arthur W. LehmanArthur W. Lehman
He had pulmonary fibrosis. He was survived by his wife, Frieda. The ART of Euphonium Playing, Volumes I and II, published by ...
https://en.wikipedia.org/wiki/Arthur_W._Lehman
BicalutamideBicalutamide
Daba MH, El-Tahir KE, Al-Arifi MN, Gubara OA (June 2004). "Drug-induced pulmonary fibrosis". Saudi Medical Journal. 25 (6): 700 ... Interstitial pneumonitis can potentially progress to pulmonary fibrosis and may be fatal. Symptoms that may indicate lung ...
https://en.wikipedia.org/wiki/Bicalutamide
Ayub ThakurAyub Thakur
"Prominent People who have died from Pulmonary Fibrosis". Pulmonary Fibrosis Foundation, Colorado. Archived from the original on ... He was suffering from pulmonary fibrosis. His funeral was held at the London Central Mosque, Regent Park, and he was laid to ...
https://en.wikipedia.org/wiki/Ayub_Thakur
Pulmonary hypertensionPulmonary hypertension
Fonseca C, Abraham D, Renzoni EA (January 2011). "Endothelin in pulmonary fibrosis". American Journal of Respiratory Cell and ... pulmonary hypertension or 'pulmonary venous hypertension'). However, in some patients, the raised pressure in the pulmonary ... American singer Pulmonary Hypertension Association Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) "Pulmonary ... Pulmonary Hypertension Wikimedia Commons has media related to Pulmonary hypertension. Scholia has a topic profile for Pulmonary ...
https://en.wikipedia.org/wiki/Pulmonary_hypertension
High-resolution computed tomographyHigh-resolution computed tomography
While HRCT may be able to identify pulmonary fibrosis, it may not always be able to further categorize the fibrosis to a ... HRCT is used for diagnosis and assessment of interstitial lung disease, such as pulmonary fibrosis, and other generalized lung ... ISBN 978-1-60795-024-0. Gotway MB, Freemer MM, King TE (June 2007). "Challenges in pulmonary fibrosis. 1: Use of high ... such as asbestosis and idiopathic pulmonary fibrosis. HRCT temporal bone is used to determine the anatomy of chronic otitis ...
https://en.wikipedia.org/wiki/High-resolution_computed_tomography
Lumleian LecturesLumleian Lectures
Scadding, J. G. (1974). "Diffuse pulmonary alveolar fibrosis". Thorax. 29 (3): 271-281. doi:10.1136/thx.29.3.271. PMC 470146. ... Diffuse pulmonary alveolar fibrosis 1974 George Algernon Smart, Monitoring in medicine 1975 Allan George Williams Whitfield, ... Gee, S. (1899). "The Lumleian Lectures on Bronchitis, Pulmonary Emphysema, and Asthma". The British Medical Journal. 1 (1995): ... Pulmonary Emphysema and Asthma 1900 Walter Butler Cheadle, On Some Cirrhoses of the Liver 1901 Joseph Frank Payne, On Cancer, ...
https://en.wikipedia.org/wiki/Lumleian_Lectures
Gordon JumpGordon Jump
He had pulmonary fibrosis. News, Deseret (January 23, 1993). "`TEACH THEM CORRECT PRINCIPLES': GOSPEL INFLUENCES LIFE, OUTLOOK ... Jump died on September 22, 2003 from pulmonary fibrosis, leading to respiratory failure at his home near Los Angeles, ... Deaths from pulmonary fibrosis, Kansas State University alumni, Male actors from Dayton, Ohio, Converts to Mormonism, Harold B ...
https://en.wikipedia.org/wiki/Gordon_Jump
Tobacco smokingTobacco smoking
Oh, CK; Murray, LA; Molfino, NL (February 2012). "Smoking and Idiopathic Pulmonary Fibrosis". Pulmonary Medicine. Hindawi ... chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), emphysema, and various types and subtypes of ... Patel, Mit P.; Khangoora, Vikramjit S.; Marik, Paul E. (October 2019). "A Review of the Pulmonary and Health Impacts of Hookah ... Laniado-Laborín, Rafael (January 2009). "Smoking and Chronic Obstructive Pulmonary Disease (COPD). Parallel Epidemics of the ...
https://en.wikipedia.org/wiki/Tobacco_smoking
Rulan Chao PianRulan Chao Pian
Pian died of pulmonary fibrosis. After her death, she was widely eulogized in various obituaries. A memorial at Harvard was ...
https://en.wikipedia.org/wiki/Rulan_Chao_Pian
Richard M. RaminRichard M. Ramin
Ramin died of pulmonary fibrosis. At his Sage Chapel memorial service, June 18, 1995, the overflow of mourners attested to the ...
https://en.wikipedia.org/wiki/Richard_M._Ramin
Smoking cessationSmoking cessation
Oh CK, Murray LA, Molfino NA (February 2012). "Smoking and idiopathic pulmonary fibrosis". Pulmonary Medicine. Hindawi ... chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), emphysema, and various types and subtypes of ... A study from Erasmus University Rotterdam limited to people with chronic obstructive pulmonary disease found that the cost- ... Laniado-Laborín R (January 2009). "Smoking and chronic obstructive pulmonary disease (COPD). Parallel epidemics of the 21 ...
https://en.wikipedia.org/wiki/Smoking_cessation
Usual interstitial pneumoniaUsual interstitial pneumonia
Pneumoconiosis Silicosis Asbestosis Idiopathic pulmonary fibrosis Pulmonary fibrosis Emphysema Travis WD, King TE, Bateman ED, ... The scarring (fibrosis) involves the pulmonary interstitium (the supporting framework of the lung). UIP is thus classified as a ... In case of idiopathic pulmonary fibrosis, certain medications like nintedanib and pirfenidone can help slow the progression. ... "Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline". American Journal of ...
https://en.wikipedia.org/wiki/Usual_interstitial_pneumonia
NitrosoureaNitrosourea
Tucci E, Verdiani P, Di Carlo S, Sforza V (1986). "Lomustine (CCNU)-induced pulmonary fibrosis". Tumori. 72 (1): 95-8. doi: ...
https://en.wikipedia.org/wiki/Nitrosourea
Restrictive lung diseaseRestrictive lung disease
... there is generally pulmonary fibrosis. Examples are: Idiopathic pulmonary fibrosis Idiopathic interstitial pneumonia, of which ... such as interstitial lung disease or pulmonary fibrosis, or from having the alveoli air spaces filled with external material ... Pulmonary function test demonstrates a decrease in the forced vital capacity. Due to the chronic nature of this disease, the ... Radiation fibrosis, usually from the radiation given for cancer treatment. Certain drugs such as amiodarone, bleomycin and ...
https://en.wikipedia.org/wiki/Restrictive_lung_disease
RocheRoche
In November Roche acquired Promedior and its lead treatment - PRM-151 - for the treatment of idiopathic pulmonary fibrosis, for ... Pulmozyme (dornase alfa), for the improvement of pulmonary function in cystic fibrosis. Raptiva (efalizumab), for psoriasis, ... Esbriet (pirfenidone), for idiopathic pulmonary fibrosis. Fansidar (sulfadoxine/pyrimethamine), for malaria and toxoplasmosis. ... "Roche to Acquire Fibrosis-Focused Promedior for up to $1.4 Billion". "Promedior Enters into Definitive Merger Agreement to be ...
https://en.wikipedia.org/wiki/Roche
List of ICD-9 codes 390-459: diseases of the circulatory systemList of ICD-9 codes 390-459: diseases of the circulatory system
415 Acute pulmonary heart disease 415.0 Acute cor pulmonale 415.1 Pulmonary embolism and infarction 415.11 Iatrogenic pulmonary ... NOS 425 Cardiomyopathy 425.0 Endomyocardial fibrosis 425.1 Hypertrophic obstructive cardiomyopathy 425.2 Obscure cardiomyopathy ... pulmonary embolism 415.19 Other pulmonary embolism and infarction 416 Chronic pulmonary heart disease 416.0 Primary pulmonary ... 416.8 Other chronic pulmonary heart diseases 416.9 Chronic pulmonary heart disease unspecified 417 Other diseases of pulmonary ...
https://en.wikipedia.org/wiki/List_of_ICD-9_codes_390–459:_diseases_of_the_circulatory_system
Firestone Institute for Respiratory HealthFirestone Institute for Respiratory Health
COPD and Respiratory Rehabilitation Pathobiology of pulmonary fibrosis Clinical trial center for idiopathic pulmonary fibrosis ...
https://en.wikipedia.org/wiki/Firestone_Institute_for_Respiratory_Health
PersinPersin
Hydrothorax and/or pulmonary oedema may be present in more severely affected animals. [..] there have been few attempts to ... At doses of person above 100 mg/kg, necrosis of myocardial fibres may occur and areas of myocardial fibrosis can be observed in ...
https://en.wikipedia.org/wiki/Persin
Health and safety hazards of 3D printingHealth and safety hazards of 3D printing
... and pulmonary fibrosis when at the nanoparticle size. A National Institute for Occupational Safety and Health (NIOSH) study ... Based on animal studies, carbon nanotubes and carbon nanofibers sometimes used in fused filament printing can cause pulmonary ...
https://en.wikipedia.org/wiki/Health_and_safety_hazards_of_3D_printing
List of diseases (C)List of diseases (C)
... diffuse Cystic fibrosis gastritis megaloblastic anemia Cystic fibrosis Cystic hamartoma of lung and kidney Cystic hygroma ... Congenital v Congenital toxoplasmosis Congenital unilateral pulmonary hypoplasia Congenital vagal hyperreflexivity Congenital ... hemidysplasia with ichthyosiform erythroderma and limbs defects Congenital hemolytic anemia Congenital hepatic fibrosis ... leukemia Chronic myelomonocytic leukemia Chronic necrotizing vasculitis Chronic neutropenia Chronic obstructive pulmonary ...
https://en.wikipedia.org/wiki/List_of_diseases_(C)
Histoplasma capsulatumHistoplasma capsulatum
It can cause pulmonary and disseminated histoplasmosis. H. capsulatum is "distributed worldwide, except in Antarctica, but most ... A particularly dangerous condition is mediastinal fibrosis, in which a subset of individuals with granulomatous mediastinitis ... Frank cases are most often seen as acute pulmonary histoplasmosis, a disease that resembles acute pneumonia but is usually self ... Schaefer, O (1966). "Pulmonary miliary calcification and histoplasmin sensitivity in Canadian eskimos". Canadian Journal of ...
https://en.wikipedia.org/wiki/Histoplasma_capsulatum
COVID-19COVID-19
organisation of exudates in alveolar cavities and pulmonary interstitial fibrosis plasmocytosis in BAL Blood and vessels: ... Infection may initiate a chain of vasoconstrictive responses within the body, including pulmonary vasoconstriction - a possible ... The main pathological findings at autopsy are: Macroscopy: pericarditis, lung consolidation and pulmonary oedema Lung findings ... of clots leading to pulmonary embolisms, and ischaemic events within the brain found as complications leading to death in ...
https://en.wikipedia.org/wiki/COVID-19
Deaths in June 2011Deaths in June 2011
Betty Roberts, 88, American politician and jurist, Oregon Supreme Court (1982-1986), pulmonary fibrosis. Paulo Renato Souza, 65 ... Jack Kevorkian, 83, American physician and right to die activist, pulmonary thrombosis. Bhajan Lal, 80, Indian politician, ...
https://en.wikipedia.org/wiki/Deaths_in_June_2011
Robert E. MurrayRobert E. Murray
Murray stated that he suffered from idiopathic pulmonary fibrosis, a scarring of the lung tissue leading to shortness of breath ...
https://en.wikipedia.org/wiki/Robert_E._Murray
BronchoconstrictionBronchoconstriction
... is common in people with respiratory problems, such as asthma, COPD, and cystic fibrosis. Medical ... Muscarinic antagonists (anti-cholinergics): Blocking the muscarinic acetylcholine receptors in pulmonary smooth muscle tissue ... Medications that stimulate the β2 receptor subtype on pulmonary smooth muscle will result in smooth muscle relaxation, ... more specifically in persistent or severe asthma and chronic obstructive pulmonary disease (COPD).[citation needed] These ...
https://en.wikipedia.org/wiki/Bronchoconstriction
Wendy BenchleyWendy Benchley
Peter Benchley died of pulmonary fibrosis on February 11, 2006 at the couple's home in Princeton, New Jersey. Wendy Benchley, ...
https://en.wikipedia.org/wiki/Wendy_Benchley
Ian ShearerIan Shearer
Shearer died from idiopathic pulmonary fibrosis at his home in Whakatāne on 1 June 2021. The Boy from the Bay: an autobiography ...
https://en.wikipedia.org/wiki/Ian_Shearer
2014 in poetry2014 in poetry
She lived with Idiopathic pulmonary fibrosis and had a double lung transplant five years before her death. May 21 - Ruth ...
https://en.wikipedia.org/wiki/2014_in_poetry
Maurice Foster (politician)Maurice Foster (politician)
He died in 2010 after a three-year battle with pulmonary fibrosis. Maurice Foster - Parliament of Canada biography "DR. MAURICE ... Deaths from pulmonary fibrosis, People from Carnduff, All stub articles, Liberal Party of Canada, Ontario MP stubs). ...
https://en.wikipedia.org/wiki/Maurice_Foster_(politician)
Endoscopic sleeve gastroplastyEndoscopic sleeve gastroplasty
... pulmonary embolism (0.06%); perforation (0.06%). Similar rates of serious adverse events were reported in the multicenter, ... "Improvement in insulin resistance and estimated hepatic steatosis and fibrosis after endoscopic sleeve gastroplasty". ...
https://en.wikipedia.org/wiki/Endoscopic_sleeve_gastroplasty
PneumonitisPneumonitis
Some degree of pulmonary fibrosis may be evident in a CT which is indicative of chronic pulmonary inflammatory processes. ... If unresolved, continued inflammation can result in irreparable damage such as pulmonary fibrosis. Pneumonitis is distinguished ... "Evaluation of the Pulmonary Patient - Pulmonary Disorders". Merck Manuals Professional Edition. Retrieved 2020-03-26. " ... incorporating pneumonia and pulmonary fibrosis as major diseases), and pneumonia as a localized infection. For most infections ...
https://en.wikipedia.org/wiki/Pneumonitis
Ross YockeyRoss Yockey
At the time of his death, he was working on a book about his experiences with Idiopathic Pulmonary Fibrosis. André Previn (1981 ...
https://en.wikipedia.org/wiki/Ross_Yockey
Malignant TumourMalignant Tumour
... split CD with Pulmonary Fibrosis 2006 R'n'R Engine - split CD/LP with Gurkha 1998 Equality!? 2008 We Are the Metal - in limited ...
https://en.wikipedia.org/wiki/Malignant_Tumour
John J. StamosJohn J. Stamos
Stamos died of pulmonary fibrosis within hours of a dinner to celebrate his coming 93rd birthday. He was buried at Memorial ...
https://en.wikipedia.org/wiki/John_J._Stamos
José Luis Rodríguez (singer)José Luis Rodríguez (singer)
He underwent a double lung transplant due to pulmonary fibrosis in December 2017. 1963: 2 Sets Con Billo 1964: Billo En ...
https://en.wikipedia.org/wiki/José_Luis_Rodríguez_(singer)
Opportunistic infectionOpportunistic infection
It is frequently associated with cystic fibrosis and hospital-acquired infections. Salmonella is a genus of bacteria, known to ... Cryptococcus neoformans is a fungus that causes cryptococcosis, which can lead to pulmonary infection as well as nervous system ...
https://en.wikipedia.org/wiki/Opportunistic_infection
DEFA4DEFA4
July 2009). "Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis". American Journal of Respiratory ...
https://en.wikipedia.org/wiki/DEFA4
Cardiac magnetic resonance imaging perfusionCardiac magnetic resonance imaging perfusion
... including acute pulmonary oedema and cardiac arrest (occurring in ≈1 in 1000 patients).[citation needed] Rieber, J. (2005). " ... as the Gadolinium contrast agent poses a very small risk of causing Nephrogenic Systemic Fibrosis (NSF) and is therefore ...
https://en.wikipedia.org/wiki/Cardiac_magnetic_resonance_imaging_perfusion
Exhaled nitric oxideExhaled nitric oxide
Children with cystic fibrosis have been found to have low eNO levels. In subjects with bronchiectasis (a state of localized, ... In the latter condition, inhaled NO is used as a diagnostic test of the response of the pulmonary arteries to vasodilators ( ... Today, NO is not only used in breath tests but also as a therapeutic agent for conditions such as pulmonary arterial ... Exhaled NO is minimally increased in chronic obstructive pulmonary disease, but levels may rise in sudden worsenings of the ...
https://en.wikipedia.org/wiki/Exhaled_nitric_oxide
Raymond C. StevensRaymond C. Stevens
The company currently has one drug in phase II clinical trials for RA and a drug in place for liver fibrosis. In 2018, Stevens ... The company currently has two drugs in clinical trials for pulmonary and metabolic diseases. Named to the PharmaVoice 100 (2022 ...
https://en.wikipedia.org/wiki/Raymond_C._Stevens
ByssinosisByssinosis
Chest radiographs show areas of opacity due to fibrosis of the pulmonary parenchyma.[citation needed] Another form of diagnosis ... a patient with byssinosis due to symptoms that are similar to other respiratory diseases such as chronic obstructive pulmonary ...
https://en.wikipedia.org/wiki/Byssinosis
Flock workers lungFlock worker's lung
... whether or not other types of flock cause this pulmonary fibrosis is not yet determined. Other types of flock include rayon, ...
https://en.wikipedia.org/wiki/Flock_worker's_lung
Eicosanoid receptorEicosanoid receptor
EP2 activation is associated with the suppression of inflammation and inflammation-induced pulmonary fibrosis reactions as well ...
https://en.wikipedia.org/wiki/Eicosanoid_receptor
Cystic fibrosis transmembrane conductance regulatorCystic fibrosis transmembrane conductance regulator
"Fifteen-year follow-up of pulmonary function in individuals heterozygous for the cystic fibrosis phenylalanine-508 deletion". ... in one copy of the CFTR gene and a cystic fibrosis-causing mutation in the other copy of CFTR. Cystic fibrosis: More than 1,800 ... The Cystic Fibrosis Transmembrane Conductance Regulator Protein The Human Gene Mutation Database - CFTR Records Cystic Fibrosis ... "Cystic fibrosis transmembrane conductance regulator and the etiology and pathogenesis of cystic fibrosis". FASEB Journal. 6 (10 ...
https://en.wikipedia.org/wiki/Cystic_fibrosis_transmembrane_conductance_regulator
Asbestos May Trigger Pulmonary FibrosisAsbestos May Trigger Pulmonary Fibrosis
Environmental or occupational exposure may be contributing to the burden of pulmonary fibrosis - even though asbestos is ... MUNICH - Some cases of idiopathic pulmonary fibrosis (IPF) may be due to environmental or occupational exposure to asbestos, ... Novel Pulmonary Delivery of Drugs for the Management of Atrial Fibrillation * Drug Stalls Lung Deterioration in Idiopathic ... Fast Five Quiz: Idiopathic Pulmonary Fibrosis * 2010/viewarticle/910730. Fast Five Quiz: Idiopathic Pulmonary Fibrosis ...
http://www.medscape.com/viewarticle/831713
Idiopathic pulmonary fibrosis: MedlinePlus GeneticsIdiopathic pulmonary fibrosis: MedlinePlus Genetics
Idiopathic pulmonary fibrosis is a chronic, progressive lung disease. Explore symptoms, inheritance, genetics of this condition ... When idiopathic pulmonary fibrosis occurs in multiple members of the same family, it is known as familial pulmonary fibrosis. ... medlineplus.gov/genetics/condition/idiopathic-pulmonary-fibrosis/ Idiopathic pulmonary fibrosis. ... Idiopathic pulmonary fibrosis is a chronic, progressive lung disease. This condition causes scar tissue (fibrosis) to build up ...
https://medlineplus.gov/genetics/condition/idiopathic-pulmonary-fibrosis/
Pulmonary Silicosis, Mixed-Dust Fibrosis | NIOSH | CDCPulmonary Silicosis, Mixed-Dust Fibrosis | NIOSH | CDC
... of free crystalline silica in conjunction with other minerals leads to a characteristic stellate nodule of mixed-dust fibrosis. ... Pulmonary Silicosis. Mixed-Dust Fibrosis. In some industrial settings, such as foundry work or coal mining, the inhalation of ... 22). There may be associated diffuse alveolar septal fibrosis and small, cellular, poorly formed silicotic nodules [Silicosis ... Cellular silicotic nodules may resemble granulomas in the early stages, with progression to massive conglomerate fibrosis in ...
https://www.cdc.gov/niosh/learning/b-reader/pathology/silicosis/2.html
Idiopathic Pulmonary Fibrosis (IPF) Guidelines: Guidelines SummaryIdiopathic Pulmonary Fibrosis (IPF) Guidelines: Guidelines Summary
Idiopathic pulmonary fibrosis (IPF) is defined as a specific form of chronic, progressive fibrosing interstitial pneumonia of ... encoded search term (Idiopathic Pulmonary Fibrosis (IPF)) and Idiopathic Pulmonary Fibrosis (IPF) What to Read Next on Medscape ... Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest. 2007 Sep. 132(3):998-1006. [QxMD MEDLINE Link]. ... Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med. 2006 Dec 25. 203(13):2895-906. [ ...
https://emedicine.medscape.com/article/301226-guidelines
The Pulmonary Fibrosis Trust - JustGivingThe Pulmonary Fibrosis Trust - JustGiving
Fundraise or donate to The Pulmonary Fibrosis Trust with JustGiving, the worlds leading online fundraising platform, helping ... The Pulmonary Fibrosis Trust. We provide personal support to people affected by Pulmonary Fibrosis. ... About The Pulmonary Fibrosis Trust. We offer practical, emotional and financial support where there is a need. We also raise ...
https://www.justgiving.com/pulmonaryfibrosistrust
Medical Definition of Fibrosis, pulmonaryMedical Definition of Fibrosis, pulmonary
Fibrosis, pulmonary: See: Pulmonary fibrosis.. CONTINUE SCROLLING OR CLICK HERE. SLIDESHOW. The 14 Most Common Causes of ...
https://www.medicinenet.com/fibrosis_pulmonary/definition.htm
A common MUC5B promoter polymorphism and pulmonary fibrosisA common MUC5B promoter polymorphism and pulmonary fibrosis
Our findings suggest that dysregulated MUC5B expression in the lung may be involved in the pathogenesis of pulmonary fibrosis ... A common polymorphism in the promoter of MUC5B is associated with familial interstitial pneumonia and idiopathic pulmonary ... for idiopathic pulmonary fibrosis. MUC5B expression in the lung was 14.1 times as high in subjects who had idiopathic pulmonary ... A common MUC5B promoter polymorphism and pulmonary fibrosis N Engl J Med. 2011 Apr 21;364(16):1503-12. doi: 10.1056/ ...
https://pubmed.ncbi.nlm.nih.gov/21506741/?dopt=Abstract
Raising awareness of covert killer: pulmonary fibrosisRaising awareness of covert killer: pulmonary fibrosis
Idiopathic Pulmonary Fibrosis - What Is Idiopathic Pulmonary Fibrosis? | NHLBI, NIHIdiopathic Pulmonary Fibrosis - What Is Idiopathic Pulmonary Fibrosis? | NHLBI, NIH
... and treatments for idiopathic pulmonary fibrosis, a condition in which your lung tissue becomes thick and stiff. ... Idiopathic pulmonary fibrosis (IPF) is a serious chronic (long term) disease that affects the tissue surrounding the air sacs, ... Other complications of IPF include pulmonary hypertension and respiratory failure, which happen when the lungs cannot deliver ... Over time, these changes can cause permanent scarring in the lungs, called fibrosis, that makes it progressively more difficult ...
https://www.nhlbi.nih.gov/health/idiopathic-pulmonary-fibrosis
idiopathic pulmonary fibrosis | News, Videos & Articlesidiopathic pulmonary fibrosis | News, Videos & Articles
GlobalNews.ca your source for the latest news on idiopathic pulmonary fibrosis . ... idiopathic pulmonary fibrosis videos and latest news articles; ... Idiopathic Pulmonary Fibrosis. * Advocates push for equal ... access to oxygen for Pulmonary Fibrosis Awareness month A Nova Scotia senior has made it his mission to draw attention to ...
https://globalnews.ca/tag/idiopathic-pulmonary-fibrosis/
Pulmonary Nocardiosis in an Immunocompetent Patient with Cystic FibrosisPulmonary Nocardiosis in an Immunocompetent Patient with Cystic Fibrosis
Patients with cystic fibrosis have pulmonary disease characterized by frequent and progressive bacterial infections. Reports of ... We report the second case to date of ,i,Nocardia transvalensis,/i, pulmonary infection in an immunocompetent patient with CF ... and underlying pulmonary disease including chronic obstructive pulmonary disease, pulmonary fibrosis, and silicosis [2]. ... S. T. Thorn, M. A. Brown, J. J. Yanes et al., "Pulmonary nocardiosis in cystic fibrosis," Journal of Cystic Fibrosis, vol. 8, ...
https://www.hindawi.com/journals/cripu/2015/984171/
New guideline developed to help physicians diagnose idiopathic pulmonary fibrosisNew guideline developed to help physicians diagnose idiopathic pulmonary fibrosis
A new international guideline has been developed to help physicians diagnosis idiopathic pulmonary fibrosis, a rare and often ... Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Lung Disease, Medicine, Oxygen, Pneumonia, Pulmonary Fibrosis, ... New guideline developed to help physicians diagnose idiopathic pulmonary fibrosis. *Download PDF Copy ... A new international guideline has been developed to help physicians diagnosis idiopathic pulmonary fibrosis (IPF), a rare and ...
https://www.news-medical.net/news/20180831/New-guideline-developed-to-help-physicians-diagnose-idiopathic-pulmonary-fibrosis.aspx
Idiopathic Pulmonary Fibrosis (IPF) Clinical Presentation: History, Physical Examination, ComplicationsIdiopathic Pulmonary Fibrosis (IPF) Clinical Presentation: History, Physical Examination, Complications
Idiopathic pulmonary fibrosis (IPF) is defined as a specific form of chronic, progressive fibrosing interstitial pneumonia of ... encoded search term (Idiopathic Pulmonary Fibrosis (IPF)) and Idiopathic Pulmonary Fibrosis (IPF) What to Read Next on Medscape ... Pulmonary hypertension is a common comorbidity in patients with idiopathic pulmonary fibrosis, and an estimated 20-40% of ... Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest. 2007 Sep. 132(3):998-1006. [QxMD MEDLINE Link]. ...
https://emedicine.medscape.com/article/301226-clinical
Idiopathic pulmonary fibrosisIdiopathic pulmonary fibrosis
... external resources Extensive lung fibrosis from usual interstitial pneumonitis ... Idiopathic Pulmonary Fibrosis (IPF), also known as Cryptogenic fibrosing alveolitis, is a chronic progressive interstitial lung ... Idiopathic pulmonary fibrosis is a type of idiopathic interstitial pneumonia (IIP), which in turn is a type (or group) of ... Pulmonary fibrosis has often been called an autoimmune disease. However, it is perhaps better characterized as an abnormal and ...
https://www.bionity.com/en/encyclopedia/Idiopathic_pulmonary_fibrosis.html
Idiopathic Pulmonary Fibrosis | Clinical Research Trial Listing ( Idiopathic Pulmonary Fibrosis ) ( TX135654 )Idiopathic Pulmonary Fibrosis | Clinical Research Trial Listing ( Idiopathic Pulmonary Fibrosis ) ( TX135654 )
Clinical trial for Idiopathic Pulmonary Fibrosis , Idiopathic Pulmonary Fibrosis ... You have been diagnosed with Idiopathic Pulmonary Fibrosis for at least 6 months ... University Hospital Clinical Trials Center is seeking volunteers who have been diagnosed with Idiopathic Pulmonary Fibrosis, a ...
https://www.centerwatch.com/clinical-trials/listings/135654/idiopathic-pulmonary-fibrosis-2/?q=idiopathic+pulmonary+fibrosis&query=idiopathic%20pulmonary%20fibrosis&featured=true&rnk=2
Home | Pulmonary Fibrosis FoundationHome | Pulmonary Fibrosis Foundation
The Pulmonary Fibrosis Foundation Registry considers the protection of your privacy to be one of our most important ... Combined, the two databases provide a wealth of data on patients diagnosed with pulmonary fibrosis (PF) or interstitial lung ... The PFF Registry is an unparalleled nationwide research study that collects data from patients living with pulmonary fibrosis ( ... Subscribe to receive the most current news and updates from the Pulmonary Fibrosis Foundation. ...
https://www.pulmonaryfibrosis.org/pff-registry
Pulmonary Fibrosis - Causes, Symptoms, Treatment, Diagnosis - MedBroadcast.comPulmonary Fibrosis - Causes, Symptoms, Treatment, Diagnosis - MedBroadcast.com
This is what happens in the lungs of people with pulmonary fibrosis. Inflammation (swelling) in the lungs usually happens ... Fibrosis refers to scar tissue that has replaced healthy tissue. ... The cause of pulmonary fibrosis, especially when it is ... Another complication of pulmonary fibrosis is pulmonary hypertension (high blood pressure in the arteries of the lungs). Scar ... Pulmonary rehabilitation is a standard part of treatment for people with pulmonary fibrosis. This can involve an exercise ...
https://www.medbroadcast.com/condition/getcondition/pulmonary-fibrosis
Fast Five Quiz: Idiopathic Pulmonary FibrosisFast Five Quiz: Idiopathic Pulmonary Fibrosis
How much do you know about idiopathic pulmonary fibrosis? Test your knowledge with this quick quiz. ... Idiopathic Pulmonary Fibrosis: Who Gets an Antifibrotic? * Genetic Analysis Shows Causal Link of GERD, Other Comorbidities to ... Pulmonary and Critical Care Fellow, Saint Louis University School of Medicine, Division of Pulmonary, Critical Care and Sleep ... Director, Division of Pulmonary and Critical Care Medicine; Director, Womens Guild Lung Institute; Executive Vice Chair, ...
https://reference.medscape.com/viewarticle/925452_6
Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in BelgiumCost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
... are recommended by international guidelines as treatment options for idiopathic pulmonary fibrosis (IPF). Objectives To compare ... "Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium," PharmacoEconomics - ... Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium. ... are recommended by international guidelines as treatment options for idiopathic pulmonary fibrosis (IPF). Objectives To compare ...
https://ideas.repec.org/a/spr/pharmo/v4y2020i3d10.1007_s41669-019-00191-w.html
Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis - Full Text View - ClinicalTrials.govInvestigating Significant Health Trends in Idiopathic Pulmonary Fibrosis - Full Text View - ClinicalTrials.gov
Pulmonary Fibrosis. Idiopathic Pulmonary Fibrosis. Fibrosis. Pathologic Processes. Lung Diseases. Respiratory Tract Diseases. ... MedlinePlus related topics: Pulmonary Fibrosis Genetic and Rare Diseases Information Center resources: Idiopathic Pulmonary ... Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis (INSIGHTS-IPF). The safety and scientific validity of ... Idiopathic Pulmonary Fibrosis in Elderly Patients: Analysis of the INSIGHTS-IPF Observational Study. Front Med (Lausanne). 2020 ...
https://clinicaltrials.gov/ct2/show/NCT01695408
Respiratory mycobiome and suggestion of inter-kingdom network during acute pulmonary exacerbation in cystic fibrosis |...Respiratory mycobiome and suggestion of inter-kingdom network during acute pulmonary exacerbation in cystic fibrosis |...
However, no NGS studies until now have characterized both communities during CF pulmonary exacerbation (CFPE). Thirty-three ... Lung infections play a critical role in cystic fibrosis (CF) pathogenesis. CF respiratory tract is now considered to be a ... Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am. J. Respir. Crit. Care Med. ... What defines a pulmonary exacerbation? The perceptions of adults with cystic fibrosis. J. Cyst. Fibros. Off. J. Eur. Cyst. ...
https://www.nature.com/articles/s41598-020-60015-4?error=cookies_not_supported
Paraquat induces pulmonary fibrosis through Wnt/β-catenin signalingParaquat induces pulmonary fibrosis through Wnt/β-catenin signaling
... pathway and myofibroblast differentiation. ... Paraquat induces pulmonary fibrosis through Wnt/β-catenin signaling pathway and myofibroblast differentiation. - GreenMedInfo ... Our study aimed to investigate the functions of the Wnt/β-catenin pathway in PQ-induced pulmonary fibrosis. By comparing the ... Inhibition of the Wnt/β-catenin signaling pathway may be investigated further as a potential fibrosis suppressor for pulmonary ...
https://greenmedinfo.com/article/paraquat-induces-pulmonary-fibrosis-through-wnt-catenin-signaling-pathway-and-
Mycobacterium chimaera Pulmonary Disease in Cystic Fibrosis Patients, France, 2010-2017 - Volume 25, Number 3-March 2019 -...
Mycobacterium chimaera pulmonary infection complicating cystic fibrosis: a case report. J Med Case Reports. 2011;5:473. DOI ... Mycobacterium chimaera Pulmonary Disease in Cystic Fibrosis Patients, France, 2010-2017 On This Page ... Mycobacterium chimaera Pulmonary Disease in Cystic Fibrosis Patients, France, 2010-2017. Emerging Infectious Diseases. 2019;25( ... Mycobacterium chimaera Pulmonary Disease in Cystic Fibrosis Patients, France, 2010-2017. Emerg Infect Dis. 2019;25(3):611-613. ...
https://wwwnc.cdc.gov/eid/article/25/3/18-1590
Pulmonary Fibrosis Support Group - VIRTUAL - WellSpan HealthPulmonary Fibrosis Support Group - VIRTUAL - WellSpan Health
Pulmonary Fibrosis Support Group - VIRTUAL. Event Details. Register Dates:. 03/15/21 05:00 PM - 06:30 PM. ... Participants can build a network of support, learn more about Pulmonary Fibrosis, receive practical information on living with ... This support group is open to anyone dealing with Pulmonary Fibrosis and their care partners. ...
https://www.wellspan.org/events/details/Pulmonary-Fibrosis-Support-Group---VIRTUAL/2836
Smoking-associated fibrosis and pulmonary asbestosis | COPDSmoking-associated fibrosis and pulmonary asbestosis | COPD
... showed interstitial fibrosis that was judged to be most consistent with smoking-associated pulmonary fibrosis. We conclude that ... The objective of the present study was to evaluate the correlation of radiographically detected pulmonary fibrosis with ... referred in consultation for asbestos-related malignancy and the presence of pulmonary fibrosis. Sixty-five cases had what was ... tissue sampling for histopathologic evaluation of asbestosis as well as an existing radiologic assessment of pulmonary fibrosis ...
https://www.dovepress.com/smoking-associated-fibrosis-and-pulmonary-asbestosis-peer-reviewed-fulltext-article-COPD
Living with Pulmonary Fibrosis FAQ | American Lung AssociationLiving with Pulmonary Fibrosis FAQ | American Lung Association
Get expert answers to some common questions from patients about living with pulmonary fibrosis. ... Is there a difference between pulmonary fibrosis and idiopathic pulmonary fibrosis (IPF)?. "Pulmonary fibrosis" is a general ... How is pulmonary fibrosis treated?. There is no cure for pulmonary fibrosis. People with IPF may benefit from a drug that slows ... Does pulmonary fibrosis spread? Is pulmonary fibrosis contagious?. PF progresses. It gets worse with time but the length of ...
https://www.lung.org/lung-health-diseases/lung-disease-lookup/pulmonary-fibrosis/patients/living-well-with-pulmonary-fibrosis/living-with-pulmonary
The rising incidence of idiopathic pulmonary fibrosis in the UK | ThoraxThe rising incidence of idiopathic pulmonary fibrosis in the UK | Thorax
interstitial fibrosis. Introduction. Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial ... postinflammatory fibrosis), and from 2000 onwards, ICD-10 code J84.1 (idiopathic pulmonary fibrosis). We used the total ... Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts. Thorax 1998;53:469-76. ... Although the validity of pulmonary fibrosis diagnoses has previously been proven in both these data sets,1 7 8 it is likely ...
https://thorax.bmj.com/content/66/6/462?ijkey=3728b2e9e924d36cb31d8cb24da58d6bd5faeafd&keytype2=tf_ipsecsha
Tolerability of nintedanib in the elderly with idiopathic pulmonary fibrosis: A single-center retrospective study | PLOS ONETolerability of nintedanib in the elderly with idiopathic pulmonary fibrosis: A single-center retrospective study | PLOS ONE
Idiopathic pulmonary fibrosis (IPF), a fibrosing interstitial lung disease, predominantly affects the elderly and is associated ...
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0262795
Rubedo Life Sciences Establishes Collaboration with Cedars-Sinai Medical Center to Advance Idiopathic Pulmonary Fibrosis...Rubedo Life Sciences Establishes Collaboration with Cedars-Sinai Medical Center to Advance Idiopathic Pulmonary Fibrosis...
Rubedo Life Sciences Establishes Collaboration with Cedars-Sinai Medical Center to Advance Idiopathic Pulmonary Fibrosis ... Rubedo Life Sciences Establishes Collaboration with Cedars-Sinai Medical Center to Advance Idiopathic Pulmonary Fibrosis ... Rubedo Life Sciences Establishes Collaboration with Cedars-Sinai Medical Center to Advance Idiopathic Pulmonary Fibrosis ... to advance its idiopathic pulmonary fibrosis (IPF) program and establish collaborative studies. ...
https://www.businesswire.com/news/home/20210601005042/en/Rubedo-Life-Sciences-Establishes-Collaboration-with-Cedars-Sinai-Medical-Center-to-Advance-Idiopathic-Pulmonary-Fibrosis-Program
Protein FoxO3 Plays Key Role in Pulmonary Fibrosis | RTProtein FoxO3 Plays Key Role in Pulmonary Fibrosis | RT
The protein FoxO3 plays a central role in idiopathic pulmonary fibrosis, according to a study ... Protein FoxO3 Plays Key Role in Pulmonary Fibrosis. Jan 12, 2018 , Pulmonary Fibrosis, Testing , ... The protein FoxO3 plays a central role in idiopathic pulmonary fibrosis, according to a study reporting that a therapy that ... How a Cystic Fibrosis Urine Test Can Help Monitor Patients Nov 30, 2022 , Cystic fibrosis ...
https://rtmagazine.com/disorders-diseases/chronic-pulmonary-disorders/pulmonary-fibrosis/protein-foxo3-key-role-pulmonary-fibrosis/
HypertensionCOPDChronicRespiratoryCases of idiopathic pulmonarPeople with idiopathic pulmonarDiagnosis of Idiopathic PulmonarTreatment of idiopathic pulmonarDiseasesLungsClinicalInflammationBleomycinIncidence of pulmonary fibrosisShortness of breDisordersPatient with Cystic FibrosisProgressive pulmonary fibrosisEpidemiologyTreat idiopathicTesting in idiopathicPatients with cystic fibrosisFamilial interstitial pneumoniaCystic fibrosis patientsGeneticAssociated with familialPathogenesisSymptoms of pulmonaryPresence of pulmonary2023ComplicationsEmphysemaOxygenResearchersTissueNintedanibExacerbationTherapeuticsLung functionFunctionPrevalenceHuman pulmonaryInflammatory2019DiffuseEpithelial cellsIdiopathic interstitial pneumonias
Hypertension10
  • pneumonia, or high blood pressure in the blood vessels that supply the lungs (pulmonary hypertension). (medlineplus.gov)
  • Pulmonary hypertension in idiopathic pulmonary fibrosis. (medscape.com)
  • Other complications of IPF include pulmonary hypertension and respiratory failure , which happen when the lungs cannot deliver enough oxygen into the bloodstream without support. (nih.gov)
  • Pulmonary hypertension is a common comorbidity in patients with idiopathic pulmonary fibrosis, and an estimated 20-40% of patients with idiopathic pulmonary fibrosis who are evaluated or listed for lung transplantation have pulmonary hypertension at rest. (medscape.com)
  • [ 4 ] Physical examination findings may be suggestive of the presence of pulmonary hypertension. (medscape.com)
  • Another complication of pulmonary fibrosis is pulmonary hypertension (high blood pressure in the arteries of the lungs). (medbroadcast.com)
  • IMSEAR at SEARO: Primary pulmonary hypertension in non-cirrhotic portal fibrosis. (who.int)
  • METHODS: Twenty two patients with NCPF underwent hemodynamic studies for pulmonary arterial pressure after excluding secondary causes of pulmonary hypertension. (who.int)
  • Pulmonary and critical care clinical trials can include COPD, cystic fibrosis, pulmonary hypertension and septic shock. (froedtert.com)
  • Pulmonary complications, namely acute chest syndrome, obstructive lung disease and pulmonary hypertension, are the most common causes of death in patients with SCA. (clinicaltrials.gov)
COPD4
  • Chronic obstructive pulmonary disease (COPD). (clevelandclinic.org)
  • Macrolides have pleomorphic effects in the lung with improvement in pulmonary function, symptoms and inflammatory markers demonstrated in several inflammatory pulmonary conditions such as cystic fibrosis, asthma, COPD and post-transplant bronchiolitis obliterans. (clinicaltrials.gov)
  • In addition HUB generated models for other diseases such as Inflammatory Bowel Disease (IBD), Chronic Obstructive Pulmonary Disease (COPD) and genetic diseases such as cystic fibrosis (CF). The company has also introduced adult stem cell-derived kidney organoids, and continues to investigate the molecular mechanisms of tissue development and cancer using organoids generated from adult Lgr5 stem cells. (corning.com)
  • We are frequently contacted by North Carolinians wondering if breathing problems like chronic obstructive pulmonary disease ("COPD"), asthma, or cystic fibrosis can qualify them to receive Social Security Disability benefits. (justicecounts.com)
Chronic17
  • Idiopathic pulmonary fibrosis is a chronic, progressive lung disease. (medlineplus.gov)
  • Idiopathic pulmonary fibrosis (IPF) is a serious chronic (long term) disease that affects the tissue surrounding the air sacs, or alveoli, in your lungs. (nih.gov)
  • Risk factors for nocardiosis include glucocorticoid use, IV drug use, previous transplant, acquired immune deficiency syndrome, and underlying pulmonary disease including chronic obstructive pulmonary disease, pulmonary fibrosis, and silicosis [ 2 ]. (hindawi.com)
  • Idiopathic Pulmonary Fibrosis (IPF) , also known as Cryptogenic fibrosing alveolitis , is a chronic progressive interstitial lung disease of unknown etiology. (bionity.com)
  • Idiopathic pulmonary fibrosis (IPF), a manifestation of chronic progressive fibrosing interstitial pneumonia,ia a rare disease. (clinicaltrials.gov)
  • Although virulence and pathogenicity of M. chimaera in lung disease are currently debated, several cases of M. chimaera lung infections have been reported in settings of chronic obstructive pulmonary disease, malignancy, or immunosuppression ( 3 - 5 ). (cdc.gov)
  • In turn, this fibrosis reduces the ability of alveoli to transport oxygen from the lungs to the bloodstream, and results in symptoms such as dyspnea, chronic dry cough, fatigue, and weight loss. (researchandmarkets.com)
  • Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease causing fibrotic remodeling of the peripheral lung, leading to respiratory failure. (jci.org)
  • I have lung cancer in my right lung, pulmonary fibrosis, peripheral neuropathy, chronic pancreatitis and just developed shingles last week. (mayoclinic.org)
  • Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and usually lethal fibrosing interstitial pneumonia of unknown cause. (archbronconeumol.org)
  • QPLS early after transplantation in our patients predicted the development of chronic rejection in patients with single-lung transplantation for emphysema and pulmonary fibrosis, whereas surgical complications, acute rejection, infection episodes, and lung function tests did not predict the outcome. (snmjournals.org)
  • Single-lung transplantation has become an effective mode of therapy for patients with end-stage chronic obstructive lung disease and pulmonary fibrosis. (snmjournals.org)
  • Idiopathic Pulmonary Fibrosis (IPF) is a rare, chronic, progressive fibrosing interstitial pneumonia that is found to affect middle-aged and older adults. (delveinsight.com)
  • Measure the effects of continued smoking on chronic pulmonary diseases. (clevelandclinic.org)
  • People with asthma, chronic obstructive pulmonary disease, or heart failure may experience worsening of their conditions and have difficulty breathing. (cdc.gov)
  • ABSTRACT Pulmonary rehabilitation is a tool that is receiving more acceptance in chronic lung diseases. (who.int)
  • A retrospective study was made in Riyadh, Saudi Arabia, on the impact of pulmonary rehabilitation on respiratory parameters and health care utilization in a group of outpatients with chronic lung diseases other than chronic obstructive pulmonary disease. (who.int)
Respiratory3
  • The clinical practice guidelines on the diagnosis of idiopathic pulmonary fibrosis were released on September 1, 2018, also by the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. (medscape.com)
  • The 4 case-patients were Caucasian, age 8-21 years, and who had a newborn diagnosis of cystic fibrosis, preexisting respiratory impairment, and digestive malabsorption. (cdc.gov)
  • A specially trained respiratory therapist usually performs pulmonary function testing. (clevelandclinic.org)
Cases of idiopathic pulmonar4
  • MUNICH - Some cases of idiopathic pulmonary fibrosis (IPF) may be due to environmental or occupational exposure to asbestos, according to a new analysis of mortality data in England and Wales. (medscape.com)
  • Only a small percentage of cases of idiopathic pulmonary fibrosis appear to run in families. (medlineplus.gov)
  • Most of the known genetic changes account for only a small proportion of cases of idiopathic pulmonary fibrosis. (medlineplus.gov)
  • The total diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis in the 7MM was 194,878 cases in 2021 which is expected to rise, at a CAGR of 1.1% during the study period (2019-2032). (delveinsight.com)
People with idiopathic pulmonar4
  • Some people with idiopathic pulmonary fibrosis develop widened and rounded tips of the fingers and toes (clubbing) resulting from a shortage of oxygen. (medlineplus.gov)
  • In people with idiopathic pulmonary fibrosis, scarring of the lungs increases over time until the lungs can no longer provide enough oxygen to the body's organs and tissues. (medlineplus.gov)
  • In people with idiopathic pulmonary fibrosis, shorter telomeres are associated with a more severe disease and a quicker decline in lung function. (medlineplus.gov)
  • It aims to improve the quality of life for people with idiopathic pulmonary fibrosis by helping healthcare professionals to diagnose the condition and provide effective symptom management. (bvsalud.org)
Diagnosis of Idiopathic Pulmonar3
  • Diagnosis of Idiopathic Pulmonary Fibrosis. (medscape.com)
  • The reported median duration of symptoms before the diagnosis of idiopathic pulmonary fibrosis is established is one to two years. (medscape.com)
  • Diagnosis of Idiopathic Pulmonary Fibrosis, some radiologic features may be more consistent with a non-IPF diagnosis due to their closer association with other ILDs. (medscape.com)
Treatment of idiopathic pulmonar2
  • Boehringer Ingelheim welcomes the international evidence-based 2015 ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis ' An Update of the 2011 Guideline. (pharmacytimes.com)
  • This review focuses on the possibilities of targeting inflammation by repurposing thalidomide for the treatment of idiopathic pulmonary fibrosis (IPF). (bvsalud.org)
Diseases14
  • Idiopathic pulmonary fibrosis belongs to a group of conditions called interstitial lung diseases (also known as ILD), which describes lung diseases that involve inflammation or scarring in the lung. (medlineplus.gov)
  • Such symptoms can be shared with a variety of pulmonary and cardiac diseases. (medscape.com)
  • [3] Autoantibodies, a hallmark of autoimmune diseases, are found in a minority of patients with truly idiopathic pulmonary fibrosis. (bionity.com)
  • Moreover, many autoimmune diseases associated with "pulmonary fibrosis", such as scleroderma, are more frequently associated with a related but more inflammatory disease, nonspecific interstitial pneumonitis. (bionity.com)
  • Idiopathic pulmonary fibrosis is a type of idiopathic interstitial pneumonia (IIP), which in turn is a type (or group) of interstitial lung diseases . (bionity.com)
  • Another condition very similar to idiopathic pulmonary fibrosis can happen in some people with certain diseases, especially autoimmune diseases like systemic lupus erythematosis or scleroderma. (medbroadcast.com)
  • Lung diseases all tend to have much the same symptoms, so a thorough history, examination, pulmonary function tests, and chest X-ray, while all essential, may not be enough to identify pulmonary fibrosis, especially if it's due to no known cause (idiopathic). (medbroadcast.com)
  • There are also people who have other diseases such as rheumatoid arthritis or lupus that can lead to pulmonary fibrosis. (lung.org)
  • The disease is usually just in the lungs but if it is the result of other diseases, the fibrosis (scarring) can be other places like in the joints. (lung.org)
  • SUNNYVALE, Calif.--( BUSINESS WIRE )-- Rubedo Life Sciences , a drug discovery company developing targeted therapeutics for age-related diseases, today announced a collaboration with Cedars-Sinai Medical Center in Los Angeles, to advance its idiopathic pulmonary fibrosis (IPF) program and establish collaborative studies. (businesswire.com)
  • Rubedo's proprietary technology platform targets age-related diseases such as Alzheimer's, diabetes, cancer, pulmonary, cardiovascular, and other disorders which have been shown in preclinical models to be driven by a progressive accumulation of senescent cells, induced by different aging factors. (businesswire.com)
  • Pulmonary Fibrosis is a one of the most common types of fibrotic lung diseases. (speakingofwomenshealth.com)
  • Pulmonary function testing is similar with the two diseases as well. (pulmonaryfibrosismd.com)
  • Pulmonary fibrosis is a disabling consequence of many lung diseases but is difficult to quantify. (cdc.gov)
Lungs16
  • This condition causes scar tissue (fibrosis) to build up in the lungs, which makes the lungs unable to transport oxygen into the bloodstream effectively. (medlineplus.gov)
  • The fibrosis that builds up in the lungs is thought to develop as a result of abnormal tissue repair following tissue damage. (medlineplus.gov)
  • Over time, these changes can cause permanent scarring in the lungs, called fibrosis, that makes it progressively more difficult to breathe. (nih.gov)
  • Honeycombing, a pattern of dense fibrosis characterized by multiple tiny air-filled spaces located at the bases of the lungs, is frequently seen in advanced cases. (bionity.com)
  • This is what happens in the lungs of people with pulmonary fibrosis. (medbroadcast.com)
  • I have pulmonary fibrosis a lung disease that HAS no cure.Yet, since I have been on Sunflower Oil (cold pressed & Unrefined) my lungs within 4 days begain to have a healing effect that even the Doctor's don't quite understand? (earthclinic.com)
  • The research showed inflammation in the lungs of the mice, and fibrosis in their lungs, which persisted following exposure. (cdc.gov)
  • Therefore, inhibiting antifibrotic conditions in the lungs with a potent antagonist of TNF-α such as adalimumab could potentially lead to interstitial pulmonary fibrosis in susceptible patients. (jrheum.org)
  • Once daily treatment with P2pal-18S reduced the severity and extent of fibrotic lesions in lungs of bleomycin-treated wild-type mice but did not further reduce fibrosis in PAR-2-deficient mice. (eur.nl)
  • Pulmonary fibrosis is a somewhat generic term that describes scarring in the lungs. (pulmonaryfibrosismd.com)
  • Idiopathic pulmonary fibrosis (IPF) is a very specific term that describes a specific disease process that leads to progressive scarring in the lungs. (pulmonaryfibrosismd.com)
  • Pulmonary function tests (PFTs) determine how well your lungs work. (clevelandclinic.org)
  • Pulmonary function testing measures how well your lungs work. (clevelandclinic.org)
  • Pulmonary function tests (PFTs) include different kinds of breathing tests that measure how well your lungs exchange air. (clevelandclinic.org)
  • Over time, the excess tissue that is built leads to fibrosis in the lungs. (epnet.com)
  • Setting aside scarring and fibrosis in the lungs, COVID-19 has been observed to form blood clots at abnormally high rates, with the potential to create pulmonary embolisms in the lower extremities, according to CNN . (rehabpub.com)
Clinical8
  • The clinical symptoms of idiopathic pulmonary fibrosis (IPF) are nonspecific. (medscape.com)
  • Winthrop University Hospital Clinical Trials Center is seeking volunteers who have been diagnosed with Idiopathic Pulmonary Fibrosis, a condition which decreases lung function. (centerwatch.com)
  • All patients had M. chimaera -positive expectorated sputum specimens, clinical symptoms of pulmonary exacerbation, or a decrease in spirometry test results that improved after specific treatment. (cdc.gov)
  • The diagnosis of pulmonary asbestosis is most often established based on clinical criteria and has both clinical and legal implications. (dovepress.com)
  • We conclude that the clinical diagnosis of mild asbestosis cannot be reliably distinguished from interstitial fibrosis in heavy smokers. (dovepress.com)
  • The diagnosis of pulmonary asbestosis is most often established on clinical grounds. (dovepress.com)
  • BACKGROUND: Clinical trials in cystic fibrosis (CF) have been hindered by the paucity of well characterised and clinically relevant outcome measures. (ox.ac.uk)
  • Hence, investment in clinical trials with a systematic plan can help repurpose thalidomide for pulmonary fibrosis . (bvsalud.org)
Inflammation5
  • However, it is perhaps better characterized as an abnormal and excessive deposition of fibrotic tissue in the pulmonary interstitium with minimal associated inflammation. (bionity.com)
  • Many other kinds of interstitial lung disease can also cause inflammation and/or fibrosis, and these are treated differently. (delveinsight.com)
  • Thalidomide interaction with inflammation in idiopathic pulmonary fibrosis. (bvsalud.org)
  • Interstitial lung disease (ILD) is a group of disorders that lead to scarring (fibrosis) and inflammation in the lung tissue. (epnet.com)
  • Recent studies suggest that lung specific inflammation is a hallmark of SCA and underlies pulmonary pathology. (clinicaltrials.gov)
Bleomycin7
  • Amiodarone, bleomycin, and nitrofurantoin are notable medications associated with pulmonary fibrosis. (medscape.com)
  • To evaluate the effects of Dengzhanshengmai (DZSM) capsules, traditional chinese medicin, on bleomycin-induced murine lung fibrosis. (ersjournals.com)
  • Pulmonary fibrosis models were generated by intratracheally instilled of bleomycin and then treated with saline and DZSM solution for 21 days respectively. (ersjournals.com)
  • DZSM capsules could improve the weakness in bleomycin-induced pulmonary fibrosis mouse models, lower the lung resistance, inhibit the inflammatory statement, decrease the hydroxyproline levels and inflammatory cytokines levels and relieve fibrosis. (ersjournals.com)
  • We addressed whether PAR-2 deficiency persistently reduces bleomycin-induced pulmonary fibrosis or merely delays disease progression and whether pharmacological PAR-2 inhibition limits experimental pulmonary fibrosis. (eur.nl)
  • Importantly, P2pal-18S treatment starting even 7 d after the onset of fibrosis limits pulmonary fibrosis as effectively as when treatment was started together with bleomycin instillation. (eur.nl)
  • In collaboration with Dr. Nathan Sandbo with the UW School of Medicine & Public Health, PEG-FUD peptide disrupts FN fibrillogenesis and collagen deposition in a bleomycin mouse model of pulmonary fibrosis. (wisc.edu)
Incidence of pulmonary fibrosis2
  • In this study, we used two different data sets to investigate whether the incidence of pulmonary fibrosis in the 21st century is still increasing in the UK. (bmj.com)
  • The aim of this study is to determine whether concomitant radiation exposure in asbestos workers increases the incidence of pulmonary fibrosis. (cdc.gov)
Shortness of bre3
  • The most common signs and symptoms of idiopathic pulmonary fibrosis are shortness of breath and a persistent dry, hacking cough. (medlineplus.gov)
  • Most people with pulmonary fibrosis first see their doctor about increasing shortness of breath during exercise. (medbroadcast.com)
  • Your healthcare provider may order pulmonary function tests if you have lung or airway symptoms like cough or shortness of breath, are undergoing surgery or use tobacco products (smoke). (clevelandclinic.org)
Disorders2
  • [5] It should be noted that these features are non-specific and can occur in a spectrum of other pulmonary disorders. (bionity.com)
  • According to both the American Thoracic Society (ATS) 1986 and 2004 statements on benign asbestos-related disorders, radiographic findings play an important role, along with exposure history, in establishing a diagnosis of pulmonary asbestosis. (dovepress.com)
Patient with Cystic Fibrosis1
  • We found 1 case of M. chimaera infection in a patient with cystic fibrosis ( 6 ). (cdc.gov)
Progressive pulmonary fibrosis1
  • Rapidly progressive pulmonary fibrosis and death ensued within 1 month while the patient was awaiting lung transplant. (jrheum.org)
Epidemiology1
  • DelveInsight's 'Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2032' report deliver an in-depth understanding of the Idiopathic Pulmonary Fibrosis , historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan. (delveinsight.com)
Treat idiopathic2
  • Australian researchers have developed a drug that mimics part of a shark's immune system to treat idiopathic pulmonary fibrosis (IPF). (pharmacytimes.com)
  • Quantitative Systems Pharmacology (QSP) software providing the ability to predict the efficacy of drugs being developed to treat idiopathic pulmonary fibrosis (IPF. (simulations-plus.com)
Testing in idiopathic1
  • Martinez FJ, Flaherty K. Pulmonary function testing in idiopathic interstitial pneumonias. (medscape.com)
Patients with cystic fibrosis3
  • Patients with cystic fibrosis have pulmonary disease characterized by frequent and progressive bacterial infections. (hindawi.com)
  • We report M. chimaera pulmonary disease in 4 patients with cystic fibrosis. (cdc.gov)
  • Rationale Loss of lung function in patients with cystic fibrosis (CF) is associated with increased mortality and varies between individuals and over time. (arizona.edu)
Familial interstitial pneumonia4
  • We then evaluated genetic variation in this region in gel-forming mucin genes expressed in the lung among 83 subjects with familial interstitial pneumonia, 492 subjects with idiopathic pulmonary fibrosis, and 322 controls. (nih.gov)
  • The odds ratios for disease among subjects who were heterozygous and those who were homozygous for the minor allele of this SNP were 6.8 (95% confidence interval [CI], 3.9 to 12.0) and 20.8 (95% CI, 3.8 to 113.7), respectively, for familial interstitial pneumonia and 9.0 (95% CI, 6.2 to 13.1) and 21.8 (95% CI, 5.1 to 93.5), respectively, for idiopathic pulmonary fibrosis. (nih.gov)
  • A common polymorphism in the promoter of MUC5B is associated with familial interstitial pneumonia and idiopathic pulmonary fibrosis. (nih.gov)
  • A polymorphism in the MUC5B gene (rs35705950) is associated with susceptibility to familial interstitial pneumonia (FIP) and idiopathic pulmonary fibrosis (IPF). (ersjournals.com)
Cystic fibrosis patients1
  • Evolution of lung function for 4 cystic fibrosis patients with Mycobacterium chimaera pulmonary disease, France, 2010-2017. (cdc.gov)
Genetic5
  • It is likely that genetic changes increase a person's risk of developing idiopathic pulmonary fibrosis, and then exposure to certain environmental factors triggers the disease. (medlineplus.gov)
  • Changes in several genes have been suggested as risk factors for idiopathic pulmonary fibrosis, while it is likely that other genetic influences have yet to be discovered. (medlineplus.gov)
  • A few families are particularly affected by idiopathic pulmonary fibrosis, which may be categorized into two forms - an environmental form and a rarer genetic form. (medbroadcast.com)
  • However, their groundbreaking research has found specific genetic changes predispose people to develop pulmonary fibrosis. (cu.edu)
  • Cystic fibrosis (CF) is a genetic disease that can be detected in newborn infants (i.e., those aged less than or equal to 1 month) by immunotrypsinogen testing. (cdc.gov)
Associated with familial1
  • There are several genes associated with familial pulmonary fibrosis, but those genes aren't present in everyone with a family history of the disease. (lung.org)
Pathogenesis6
  • Our findings suggest that dysregulated MUC5B expression in the lung may be involved in the pathogenesis of pulmonary fibrosis. (nih.gov)
  • Oxidant stress from smoking may damage alveolar epithelial cells and contribute to the pathogenesis of idiopathic pulmonary fibrosis. (medscape.com)
  • Lung infections play a critical role in cystic fibrosis (CF) pathogenesis. (nature.com)
  • Lung infections play a critical role in cystic fibrosis (CF) pathogenesis where they can lead to significant acute decrease of lung function, known as CF pulmonary exacerbation (CFPE). (nature.com)
  • In summary, these assays indicated that Wnt/β-catenin signaling pathway played a regulatory role in the differentiation of lung epithelial cells and fibroblasts, and the pathogenesis of pulmonaryfibrosis related to PQ. (greenmedinfo.com)
  • The lead analyst of the report commented "The global anti-idiopathic pulmonary fibrosis drugs market is driven by the rising prevalence and incidence of IPF patients, expected launch of novel therapies, special regulatory (Orphan and Fast-track) designations for pipeline molecules, increased understanding of disease pathogenesis, and limited number of current players. (visiongain.com)
Symptoms of pulmonary1
  • For the majority of people, the symptoms of pulmonary fibrosis come on slowly over the course of months to years, but for some people the symptoms can develop more rapidly. (medbroadcast.com)
Presence of pulmonary1
  • We examined the slides of 186 cases with reported asbestos exposure, referred in consultation for asbestos-related malignancy and the presence of pulmonary fibrosis. (dovepress.com)
20231
  • Fast Five Quiz: Idiopathic Pulmonary Fibrosis - Medscape - Feb 24, 2023. (medscape.com)
Complications2
  • Pulmonary fibrosis can lead to several severe complications. (medbroadcast.com)
  • To date, no therapy has been shown to improve the pulmonary complications of SCA. (clinicaltrials.gov)
Emphysema1
  • mean age, 54.6 ± 6.0 y) who underwent single-lung transplantation for emphysema (n = 14) or pulmonary fibrosis (n = 4) were studied. (snmjournals.org)
Oxygen3
  • Oxygen therapy and pulmonary rehabilitation are key components of maintaining a good quality of life with PF. (lung.org)
  • The mainstay of treatment would be supplemental oxygen and pulmonary rehabilitation, if needed. (speakingofwomenshealth.com)
  • A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI . (bvsalud.org)
Researchers5
  • Researchers have also examined environmental risk factors that could contribute to idiopathic pulmonary fibrosis. (medlineplus.gov)
  • Our program enables researchers, for the first time, to explore what treatment strategies work best for patients and to find new ways to prevent, diagnose, treat, and potentially cure pulmonary fibrosis. (pulmonaryfibrosis.org)
  • Such effects are similar to the interstitial pulmonary fibrosis reported previously by NIOSH researchers using single-walled carbon nanotubes. (cdc.gov)
  • Marilyn Glassberg recently travelled to San Francisco to attend the American Thoracic Society's (ATS) 2016 International Conference (13-18 May 2016) alongside 15,000 other pulmonary, critical care, and sleep researchers. (biomedcentral.com)
  • The reason, researchers say, is the fibrosis known to occur in SARS and MERS patients. (rehabpub.com)
Tissue13
  • Fibrosis refers to scar tissue that has replaced healthy tissue. (medbroadcast.com)
  • Sixty-five cases had what was judged to be adequate tissue sampling for histopathologic evaluation of asbestosis as well as an existing radiologic assessment of pulmonary fibrosis by B-reader report. (dovepress.com)
  • Pulmonary fibrosis" is a general term that can apply to scarring or stiffening of the lung tissue from a number of different reasons. (lung.org)
  • Scientists also know that several proteins that promote lung tissue scarring, or fibrosis, are involved in myofibroblast overproduction. (rtmagazine.com)
  • Idiopathic pulmonary fibrosis (IPF) is a type of interstitial lung disease in which scarring and thickening of the lung tissue occurs due to unknown causes. (researchandmarkets.com)
  • Single-cell RNA sequencing of pulmonary epithelial cells isolated from IPF lung tissue demonstrated altered expression of LncRNAs, including increased MEG3. (jci.org)
  • By integrated multiscale biomechanical and biological analyses of idiopathic pulmonary fibrosis lung tissue, we identify that increased tissue stiffness is a function of dysregulated post-translational collagen cross-linking rather than any collagen concentration increase whilst at the nanometre-scale collagen fibrils are structurally and functionally abnormal with increased stiffness, reduced swelling ratio, and reduced diameter. (elifesciences.org)
  • In ex vivo and animal models of lung fibrosis, dual inhibition of lysyl oxidase-like (LOXL) 2 and LOXL3 was sufficient to normalise collagen fibrillogenesis, reduce tissue stiffness, and improve lung function in vivo. (elifesciences.org)
  • Idiopathic pulmonary fibrosis (IPF) is a devastating disease of the lung, which scars the tissue and gradually destroys the organ, ultimately leading to death. (elifesciences.org)
  • My specific area of interest is idiopathic pulmonary fibrosis (IPF), an incurable and fatal disease characterized by a progressive cycle of pathologic connective tissue accumulation and scar tissue formation. (biomedcentral.com)
  • It affects lung tissue (alveoli in particular) by either thickening, stiffening, or persistent and progressive scarring (fibrosis), which increases irreversibly over time. (delveinsight.com)
  • Imaging revealed multiple complete and bifid tracheal rings throughout the level of the stenosis, with associated areas of mucosal ulceration and tracheal wall fibrosis, the latter believed to result from prolonged ventilation and resultant tissue granulation. (bmj.com)
  • We hypothesized that the abundance of lucifer yellow-stained matrix macromolecules in lung tissue sections could be measured by laser scanning confocal microscopy, would reflect differences between varying degrees of pulmonary fibrosis, and could be compared directly to biochemical measurements of lung collagen. (cdc.gov)
Nintedanib3
  • Background Nintedanib (Ofev®) and pirfenidone (Esbriet®) are recommended by international guidelines as treatment options for idiopathic pulmonary fibrosis (IPF). (repec.org)
  • Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium ," PharmacoEconomics - Open , Springer, vol. 4(3), pages 449-458, September. (repec.org)
  • Changes in the percentages of circulating endothelial cells ( CEC ), endothelial progenitor cells ( EPC ) and circulating fibrocytes in patients with idiopathic pulmonary fibrosis treated with nintedanib after 6 months of treatment. (biomedcentral.com)
Exacerbation4
  • The association of an increased cough and sputum production, breathlessness, and fatigue with a reduction in forced expiratory volume in 1 s (FEV1) or forced vital capacity (FVC) was diagnosed as pulmonary exacerbation ( 7 ) for all patients ( Figure ). (cdc.gov)
  • However, no NGS studies until now have characterized both communities during CF pulmonary exacerbation (CFPE). (nature.com)
  • Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation. (ox.ac.uk)
  • 10 years) treated for a physician-defined exacerbation of CF pulmonary symptoms. (ox.ac.uk)
Therapeutics1
  • This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. (clickpress.com)
Lung function3
  • What do the breathing test (pulmonary or lung function tests) numbers mean? (lung.org)
  • Objectives To develop simple pulmonary outcome prediction (POP) tools to estimate lung function at age 6 in patients aged 2-5 years (POP 2-5 ) and lung function change over a 4-year period in patients aged 6-17 years (POP 6-17 ). (arizona.edu)
  • Another name for pulmonary function tests is lung function tests. (clevelandclinic.org)
Function23
  • The key issue facing clinicians is whether the presenting history, symptoms/signs, radiology, and pulmonary function testing are collectively in keeping with the diagnosis of IPF (which carries the relatively poor prognosis described above) or whether the findings are due to another process. (bionity.com)
  • Unfortunately, one of the confounding features in the diagnosis may be a history of cigarette abuse, which can produce interstitial opacities on chest imaging as well as diffusion defects on pulmonary function testing, criteria that are used in the diagnosis of pulmonary asbestosis. (dovepress.com)
  • The results of a pulmonary function test are measured in comparison to the average performance of other individuals of the same age, height and weight. (lung.org)
  • Thus, in human fibrosis, altered collagen architecture is a key determinant of abnormal ECM structure-function, and inhibition of pyridinoline cross-linking can maintain mechano-homeostasis to limit the self-sustaining effects of ECM on progressive fibrosis. (elifesciences.org)
  • Patients were evaluated using QPLS and pulmonary function tests before surgery and at 1-3 mo and 1-3 y after transplantation. (snmjournals.org)
  • Pulmonary function tests are performed to assess for restrictive lung disease which is characterized by decreased lung volumes (especially decreased forced vital capacity, total lung capacity, and functional residual capacity) and decreased diffusion capacity. (delveinsight.com)
  • Spirometry is a common pulmonary function test. (clevelandclinic.org)
  • What are pulmonary function tests? (clevelandclinic.org)
  • What is the most common pulmonary function test? (clevelandclinic.org)
  • When is pulmonary function testing performed? (clevelandclinic.org)
  • Even if you don't have symptoms, your healthcare provider may order a pulmonary function test as part of a routine physical examination . (clevelandclinic.org)
  • When would pulmonary function testing be needed? (clevelandclinic.org)
  • Who performs pulmonary function testing? (clevelandclinic.org)
  • How does pulmonary function testing work? (clevelandclinic.org)
  • A pulmonary function test is relatively simple. (clevelandclinic.org)
  • How do I prepare for a pulmonary function test? (clevelandclinic.org)
  • Can you eat before a pulmonary function test? (clevelandclinic.org)
  • What should I expect on the date of pulmonary function testing? (clevelandclinic.org)
  • You'll take a PFT at a pulmonary function lab at an outpatient office or a hospital. (clevelandclinic.org)
  • What should I expect during pulmonary function testing? (clevelandclinic.org)
  • Investigators hypothesize that low dose macrolide therapy is well tolerated and can improve pulmonary function and symptoms in patients with SCA. (clinicaltrials.gov)
  • Calculation of the coefficient of variation for FEV1 % predicted will be essential for the interpretation of clinically and statistically meaningful changes in spirometry for participants who are treated with azithromycin to improve their baseline pulmonary function when compared to controls. (clinicaltrials.gov)
  • The morphology domain is divided into three sections: interstitial pneumonia patterns suggested by HRCT imaging, histopathologic features identified by surgical lung biopsy, or evidence of additional thoracic compartment involvement as determined by diagnostic imaging, histopathologic findings, right heart catheterization (RHC) or pulmonary function testing. (medscape.com)
Prevalence4
  • Idiopathic pulmonary fibrosis has an estimated prevalence of 13 to 20 per 100,000 people worldwide. (medlineplus.gov)
  • Physicians should pay attention to historical clues that may suggest the presence of obstructive sleep apnea (OSA) because a 2009 study demonstrated the high prevalence of OSA in patients with idiopathic pulmonary fibrosis. (medscape.com)
  • [ 37 ] Therefore, the prevalence of OSA in this sample was 88%, suggesting that OSA in patients with idiopathic pulmonary fibrosis may have been previously underrecognized. (medscape.com)
  • Objectives The prevalence of idiopathic pulmonary fibrosis (IFF) tends to be greater in the elderly although the precise outcome is not known. (go.jp)
Human pulmonary1
  • Expression of MEG3 in human pulmonary epithelial cell lines increased basal cell-associated RNAs, including TP63, KRT14, STAT3, and YAP1, and enhanced cell migration, consistent with a role for MEG3 in regulating basal cell identity. (jci.org)
Inflammatory4
  • Lung tissues were collected after the mice were killed and observed following staining with H&E solution or Masson's solution to estimate the inflammatory level and fibrosis degree respectively. (ersjournals.com)
  • Furthermore, the inflammatory state and fibrosis level were also relieved in pathological specimens. (ersjournals.com)
  • Disease activity was assessed using 46 assays across five key domains: symptoms, lung physiology, structural changes on CT, pulmonary and systemic inflammatory markers. (ox.ac.uk)
  • We have explored topics such as the role of support measures and palliative care, pulmonary manifestations of Sjogren's syndrome, idiopathic inflammatory myopathies and the treatment of cough in idiopathic pulmonary fibrosis. (hopkinsmedicine.org)
20191
  • The Idiopathic Pulmonary Fibrosis market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted 7MM Idiopathic Pulmonary Fibrosis market size from 2019 to 2032. (delveinsight.com)
Diffuse2
  • Microscopic examination of the sample was positive for diffuse interstitial fibrosis ( Figure 2 ). (jrheum.org)
  • Idiopathic pulmonary fibrosis is the most devastating diffuse fibrosing lung disease that remains refractory to therapy. (eur.nl)
Epithelial cells1
  • Peripheral pulmonary epithelial cells lose normal alveolar epithelial gene expression patterns and variably express genes associated with diverse conducting airway epithelial cells, including basal cells. (jci.org)
Idiopathic interstitial pneumonias1
  • Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias. (bmj.com)
Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (paper.li)
Hermansky-Pudlak Syndrome: Background, Pathophysiology, Epidemiology
Hermansky-Pudlak Syndrome: Background, Pathophysiology, Epidemiology (medscape.com)
DKC1 gene: MedlinePlus Genetics
DKC1 gene: MedlinePlus Genetics (medlineplus.gov)
Statement by 36 Patient Organizations in Opposition to Senate's Proposed Weakening of the Orphan Drug Tax Credit - National...
Statement by 36 Patient Organizations in Opposition to Senate's Proposed Weakening of the Orphan Drug Tax Credit - National... (rarediseases.org)
Cellular crosstalk regulates the aqueous humor outflow pathway and provides new targets for glaucoma therapies | Nature...
Cellular crosstalk regulates the aqueous humor outflow pathway and provides new targets for glaucoma therapies | Nature... (nature.com)
Idiopathic Pulmonary Fibrosis (IPF): Practice Essentials, Background, Pathophysiology
Idiopathic Pulmonary Fibrosis (IPF): Practice Essentials, Background, Pathophysiology (medscape.com)
Interstitial (Nonidiopathic) Pulmonary Fibrosis: Background, Pathophysiology, Etiology
Interstitial (Nonidiopathic) Pulmonary Fibrosis: Background, Pathophysiology, Etiology (medscape.com)
Idiopathic Pulmonary Fibrosis Imaging: Practice Essentials, Radiography, Computed Tomography
Idiopathic Pulmonary Fibrosis Imaging: Practice Essentials, Radiography, Computed Tomography (medscape.com)
Terapêutica complementar | Life with pulmonary fibrosis
Terapêutica complementar | Life with pulmonary fibrosis (lifewithpulmonaryfibrosis.com)
(emedicine.medscape.com)
Idiopathic Pulmonary Fibrosis (IPF) Among Dental Personnel | NIOSH | CDC
Idiopathic Pulmonary Fibrosis (IPF) Among Dental Personnel | NIOSH | CDC (cdc.gov)
Idiopathic Pulmonary Fibrosis | Clinical Research Trial Listing ( Idiopathic Pulmonary Fibrosis ) ( TX135654 )
Idiopathic Pulmonary Fibrosis | Clinical Research Trial Listing ( Idiopathic Pulmonary Fibrosis ) ( TX135654 ) (centerwatch.com)
Fast Five Quiz: Idiopathic Pulmonary Fibrosis
Fast Five Quiz: Idiopathic Pulmonary Fibrosis (medscape.com)
DailyMed - AMIODARONE HYDROCHLORIDE injection, solution
DailyMed - AMIODARONE HYDROCHLORIDE injection, solution (dailymed.nlm.nih.gov)
Interstitial Lung Disease - HealthLibrary
Interstitial Lung Disease - HealthLibrary (healthlibrary.epnet.com)
Fast Five Quiz: Differential Diagnosis of IPF
Fast Five Quiz: Differential Diagnosis of IPF (medscape.com)
New and Effective Treatments for IPF
New and Effective Treatments for IPF (medscape.com)
Idiopathic Pulmonary Fibrosis Linked to Extended Asbestos Exposure | Asbestos Ships
Idiopathic Pulmonary Fibrosis Linked to Extended Asbestos Exposure | Asbestos Ships (asbestos-ships.com)
Advances in Translational Models to Study Fibrosis | The New York Academy of Sciences
Advances in Translational Models to Study Fibrosis | The New York Academy of Sciences (nyas.org)
Issue: Molecular Therapy
Issue: Molecular Therapy (cell.com)
Donations for the Canadian Pulmonary Fibrosis Foundation | Indiegogo
Donations for the Canadian Pulmonary Fibrosis Foundation | Indiegogo (indiegogo.com)
NHLBI Supports CADET Researchers to Produce New Pulmonary Disease Drugs (Part 2) | NHLBI, NIH
NHLBI Supports CADET Researchers to Produce New Pulmonary Disease Drugs (Part 2) | NHLBI, NIH (nhlbi.nih.gov)
Scleroderma Treatment & Management: Approach Considerations, Pruritus, Raynaud Phenomenon
Scleroderma Treatment & Management: Approach Considerations, Pruritus, Raynaud Phenomenon (medscape.com)